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ABSTRACT 
C6o Amino Acids and Peptides 
Since the discovery of the buckyball in 1985, researchers have imagined its potential in 
fields ranging from materials science to medicinal chemistry. The unique size, shape and 
hydrophobicity of C60 fullerene endow it with the ability to interact with biological 
superstructures such as enzymes and membranes making it attractive as a potential 
pharmacophore. In this regard, we have developed a new, simple route to water soluble fullerene 
amino acids, both alkyl and aryl, through the dipolar addition of azido starting materials. The 
synthesis of our phenylalanine derivative, including the chromatographic purification, requires 
only one day for its completion. We have subsequently used our C6o phenylalanine derivative in 
the synthesis of a series of C6o peptides for the purposes of enzyme inhibition, specifically 
human immunodeficiency virus Type 1 protease, a critical viral enzyme responsible for the 
maturation of the virus and a popular target of medicinal chemists. We have demonstrated the 
ability of our C6o amino acids and peptides to inhibit HIV -1 PR in a cell-free fluorescence based 
assay at low nanomolar concentrations. 
Graphite, or specifically graphene, has recently come to the forefront of nanomaterials 
research due to it similar scale, properties, and reaction pathways as other more costly carbon 
nanostructures such as carbon nanotubes. We have demonstrated the high yield functionalization 
of graphitic starting materials through the thermal decomposition of azido amino acids to their 
corresponding nitrene. The result is an inexpensive, highly functionalized, carbon based scaffold. 
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Introduction 
Amino acids are one of the most basic and important building blocks of life. Most 
were discovered over a century ago when proteins were boiled in hot acids and the more 
simple products of the reaction crystallized out of solution. 1 The first amino acid 
discovered in nature and then isolated by a group of French chemists was from asparagus 
roots and was so called asparagine. 2 Not to be left out, Japanese chemists soon led the 
way in determining the identity and properties of amino acids after the discovery that 
glutamate was responsible for the savory umami taste. 3 During the time of their discovery 
and characterization, amino acids and the proteins they came from were considered quite 
baffling substances to early chemists. Figure 1.1 shows the generic structure of an amino 
acid composed of a tetrahedral, a-carbon center attached to an amino group, a carboxyl 
group, a hydrogen atom, and an R side chain, which imparts the overall structure with its 
unique properties. At biological pH (7 .4) an individual amino acid exists as a zwitterion, 
charged at both ends but overall neutral. 
amino 
H 
\ 
+ H N 
/ 
H 
hydrogen 
carboxyl 
H 0 
I ~ C - C 
I ~ o-
R 
R-group 
(variant) 
Figure 1.1. The generic base structure of all of the twenty naturally occurring amino 
acids.4 
2 
There are twenty, naturally occurring common amino acids found in proteins with 
distinct properties due to their structural difference in their R sidechain. Of the twenty 
naturally occurring amino acids, ten are essential for human life. 5 Figure 1.2 shows the 
structures all of the amino acids along with their classification as either: nonpolar or 
aliphatic, polar but neutral, acidic or negatively charged, and basic or positively charged. 
The naturally occurring amino acids found in proteins are a-amino acids, meaning the 
carboxy, amino, R sidechain, and hydrogen moieties are attached to the alpha carbon 
imparting chirality to the structure (except glycine where R is hydrogen). As may be 
evident by their structures, the identity of the R sidechain controls the properties of the 
amino acid. For instance, the non-polar or aliphatic amino acids are hydrophobic in 
nature and therefore tend to reside in the hydrophobic core of a protein or within lipid 
membranes. 5 
The discovery that amino acids are asymmetric or chiral necessitated the 
development of a suitable nomenclature system. As a result both the DIL and R/S 
systems were developed. The D/L system is based on the principal that enantiomers, non-
superimposable mirror images, rotate plane polarized light in different directions but to 
the same degree.5 Clockwise rotation (+) of the incident light is designated as 
dextrorotatory whereas counterclockwise rotation ( -) is referred to as levorotatory; 
however, this is not what the D/L system refers to. The DIL system uses D and L 
glyceraldehyde as a reference for all other carbon based molecules. 5 Given that all 
protein-derived amino acids are of the L configuration but some are dextrorotatory and 
some are levorotatory, this naming system can be confusing. In the R/S system, priorities 
are given to the chiral carbon substituents based on atomic number. Atoms with higher 
atomic numbers are given the higher priority.5 The R/S system is less ambiguous and 
therefore will be used in the remainder of this discussion. 
onpolar, aliphatic R groups 
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3 
Figure 1.2. The structures of the twenty common am1no acids along with their 
classification. The R -side is highlighted in pink. 6 
In addition to the twenty common amino acids, there are several that occur only 
rarely in proteins, such as hydroxylysine and hydroxyproline, which are found in collagen 
and gelatin proteins. 5 Other minor alterations to the common amino acid structures 
include methylation in certain muscle proteins and phosphorylation of amino acids 
4 
involved in cell growth and regulation. 5 All of these variations on the common amino 
acid structure are found in proteins; however, there are still many biochemically 
important amino acids and derivatives not found in proteins. Some examples are the 
neurotransmitters y-aminobutyric acid (GABA) and serotonin, and the hormone 
epinephrine. 5 
Amino acids polymerize in a head to tail fashion through their identifying 
functional groups, NH2 and COOH, in a condensation reaction forming an amide bond, 
also referred to as a peptide bond (Figure 1.3). The nitrogen is in resonance with the 
carboxy group preventing free rotation around the peptide bond and resulting in the 
partial double bond character of peptide bonds. The structures formed by the 
polymerization of amino acids are designated as peptides when they are short polymers, 
polypeptides when several dozen amino acids are present, and proteins when they consist 
of one or more polypeptide chains. 5 
N-terminus C-terminus 
Figure 1.3. The polymerization of amino acids into peptides is presented above with the 
peptide bond highlighted in red. 
A protein has several levels of structural organization. When composed of one 
peptide chain they are monomeric, when composed of multiple peptide chains they are 
5 
referred to as multimeric. When a protein is composed of two identical monomers, it is 
called a homodimer. The architecture of a protein can be quite complex, but can be 
clarified by designating various levels of organization. The primary structure is simply 
the sequence of amino acids present. Non-covalent interactions, such as H-bonding, 
between polypeptide chains form the secondary structure. The overall 2° structure is 
organized into new specific structures such as a.-helices and 13-sheets having the specific 
properties imparted by the amino acid sequence. When the polypeptide chains bend and 
fold they form a compact, three-dimensional structure designated as the tertiary structure. 
When multiple 3° structures interact with each other they form the quaternary protein 
structure. The conformation of a protein refers to its overall protein architecture and it 
quaternary structure is the functional unit of almost all cellular functions. 5 
One subset of the functional quaternary protein structures, and by far the largest, 
is enzymes. Enzymes function to catalyze biological reactions and do so with enviable 
efficiency from a chemist's point of view. Enzymes can improve biological reaction rates 
by as much as 1016 times the uncatalyzed reaction.5 For example, DNA synthesis requires 
the decarboxylation of orotidine monophosphate (OMP). The uncatalyzed half-life of the 
decarboxylation of OMP is approximately 78 million years, while the enzyme catalyzed 
reaction half-life is 18 milliseconds.7 Enzymes are usually conveniently named according 
to the nature of the reaction they catalyze. For instance the enzyme responsible for 
catalyzing the decarboxylation of OMP is called OMP decarboxylase. Enzymes are not 
just essential to sustaining life in the human body but also in sustaining disease. 
When a person is infected with a virus such as human immunodeficiency virus 
(HIV) or hepatitis C virus (HCV), otherwise healthy cells are reprogrammed by the virus 
to produce viral proteins/enzymes. The viral enzymes function for the virus in the same 
manner as they do in healthy cells by catalyzing otherwise kinetically unfavorable 
reactions. A virus is not always the reason for dysfunctional enzymes; sometimes the 
body overproduces an enzyme leading to disease or enzyme point mutations cause it to 
6 
malfunction.7 For these reasons, enzymes have become a common target for medicinal 
chemists. In fact, in 2002, almost half of all marketed small molecule drugs functioned as 
enzyme inhibitors.7 
It was widely believed that the sequencing of the human genome would bring 
about bountiful targets for drug therapy. In fact, ofthe some 30,000 proteins encoded for 
by the human genome, only about 10% are considered to be "druggable".7 The term 
"druggable" refers to the ability of a target to fold into conformations able to interact 
specifically with small drug-like molecules. 8 Of those 3000 "druggable" targets, only 
about 600 - 1500 of them are considered to be "disease modifying", with a large 
percentage of them being enzymes.7 Given that in many cases the substrate of a given 
enzyme is known, medicinal chemists are essentially provided with a roadmap to 
inhibition. Hence the popularity of enzymes as targets for drug therapy. However, many 
proteins interact only with other proteins, not small drug-like molecules. These targets 
were widely considered by pharmacologist to be unlikely targets for inhibition by small 
molecule drug therapy.8 In those cases it became necessary to tap a source of otherwise 
non-classical drug molecules, such as peptides and antibodies, as pharmacophores. 
Drugs built on a peptide base are not without their drawbacks. Peptides tend not 
to be able to survive the acidic environment of the gastrointestinal tract and therefore 
must be delivered in some other, usually uncomfortable, means such as injection.9 
Regardless, there are countless peptide drugs on the market today. A few examples 
include insulin, the first and most commonly prescribed peptide drug, for the treatment of 
diabetes, interferon for the treatment of multiple sclerosis and hepatitis, and 
erythropoietin for the treatment of the chronic anemia experienced by patients in renal 
failure.9 While peptides as drugs do present some limitations, they also possess many 
advantages. 
If protein interfaces determine the interactions between a protein and its substrate, 
then logically a compound mimicking that interface should compete with the natural 
7 
substrate. Peptides as enzyme inhibitors have the benefit of a structure that is inherently 
compatible with a protein's active site. As it turns out, a relatively small number of amino 
acids typically govern the interactions of protein-protein interfaces; among them are 
proline (Pro), isoleucine (Ile), tyrosine (Tyr), tryptophan (Trp), asparagine (Asn) and 
arginine (Arg).8 What this means is that only a small number of amino acids may be 
critical for molecular recognition of a peptide inhibitor. If problems with stability, 
delivery, and specificity cannot be overcome, a peptide inhibitor can also serve as a guide 
for the synthesis of non-peptidic inhibitors. 
One issue of many drug molecules is their inability to cross a membrane, whether 
that is a cell membrane or the blood-brain barrier. In fact a set of guidelines called 
Lipinski's rule of five was established and widely recognized for evaluating the "drug 
likeness" of compounds.10 The main goal of these guidelines is to predetermine if a drug 
candidate will be orally bioavailable and whether it will have the ability to permeate cell 
membranes. But there is another solution to this problem of permeability that lies in the 
field of nanotechnology. 
Since its discovery in 198511 and bulk production in 1990,12 C6o fullerene has 
captured the imagination of researchers. The given name of the unique molecule is 
Buckminsterfullerene and the IUP AC method of naming distinguishes it as 
hentriacontacyclo[29 .29 .0.02,14 .03,12 .04,59 .05,10 .06,58 .O 7,55 .08,53 .09,21 .011,2o .Ol3,18 .015,30 .016,28 .01 
7,25.019,24 .022,52 .023,50 .026,49.027,47 .029,45 .032,44 .033,60 .034,57.035,43 .036,56.037,41.038,54.039,51.040,48.04 
2,46]hexaconta-1 ,3,5(1 0),6,8, 11, 13,(18), 14, 16,19,21 ,23,25,27 ,29( 45),30,32,( 44),33, 5( 43), 
36,38(54),39(51),40(48),41,46,49,52,55,57,59-triacontaeneY But for the purposes of this 
discussion the more convenient names Buckyball, fullerene, and C6o refer exclusively to 
C6o fullerene and are used interchangeably. 
Consisting entirely of fused hexagons and pentagons, the class of molecules 
called fullerenes have a curved shaped, as a result of the pentagons, and are the only 
allotropes of carbon that are soluble in organic solvents at room temperature. 
8 
Specifically, C6o has twelve pentagons and twenty hexagons gtvmg it a perfectly 
spherical shape with all of the pentagons isolated by hexagons (Figure 1.4). The bonds of 
[6,6] junctions, where the electron density is centered, are shorter than the bonds of [5,6] 
junctions. 13 The strained shape of C6o along with its electron deficiency and conjugated 
system of double bonds make it an extremely reactive molecule in nucleophillic 
additions, cycloadditions, radical additions, reductions and many others. 13 The outer 
diameter of C6o with its associated electron cloud is 10.34 A or 1.034 nm. Some might 
call C6o the original nanoparticle. 
Figure 1.4. The structure of C6o fullerene (Buckyball). 
The unique 1 nm size, spherical shape and electrostatic properties of C6o have 
sparked interest in the novel molecule spanning multiple scientific disciplines from 
materials science to medicinal chemistry. The many known and potential applications of 
C6o are too broad and diverse a topic for one discussion; therefore, this one will focus on 
some of the biological applications of C6o derivatives. 
One hurdle early fullerene chemists had to overcome in the study of the biological 
applications of fullerenes was the aqueous solubility of C60 or rather the lack there of. 
However, progress in the field has all but eliminated the problem of solubility through 
derivitization with polar substituents, dendrimers, and biomolecules, opening the door to 
9 
a wide range of biological applications including photodynamic therapy, DNA cleavage, 
and enzyme inhibition. 14 
The size and shape of C6o endow it with the unique ability to interact with 
biological superstructures such as enzymes and receptors. 15 Friedman was the first to 
propose the fit C6o with an enzyme active site, specifically the hydrophobic binding 
pocket of HIV -1 protease, during the height of Bucky mania. 16 Since then researchers 
have investigated inhibition of glutathione-S-transferase, microsomal cytochrome P450-
dependent monooxygenases and nitric oxide reductase. 17 In our laboratory a fullerene 
amino acid, Baa (Figure 1.5), was developed and used to synthesize series of fullerene 
peptides through solid phase peptide synthesis (SPPS). 18 We have since reported the 
potent inhibition of HIV -1 protease and carbonic anhydrase by Baa and its amino 
protected derivatives. 19 
~OH N~ H~'Boc 
H 
Figure 1.5. The structure above is Boc-Baa, an amino protected C6o amino acid. 18 
Coming back to the need for improved membrane permeability for drug 
molecules, C60 and derivatives of C60 have been shown to be membranotropic.20 The Baa 
peptides synthesized in our laboratory were shown not only to facilitate the transport of 
its peptide cargo, easily crossing the cell membrane, but also to cross another physical 
barrier, porcine skin.21 In addition to crossing the cellular membrane, fullerene 
derivatives have also been shown to cross the blood brain barrier, a major challenge in 
the treatment of brain disorders.22 These discoveries present a novel approach to the issue 
10 
of membrane penetration by drug therapeutics; however, smce the rise of 
nanotechnology, there has been much concern about the biological and environmental 
fate of nanomaterials. 23 
There has been some debate about the toxicity of C6o, limiting its use in biological 
applications. Initial reports claiming that C60 was toxic to human cells and largemouth 
bass utilized aqueous dispersions of "nano-C6o" and determined that the method of 
sample preparation and surface derivativitization influenced the toxicological findings.24 
These early studies have since been called into question by several subsequent reports 
showing that the toxicity was not due to C6o but instead to the polar organic solvents 
trapped between the C6o crystallites?5 In fact, one similar study utilizing aqueous C6o 
dispersions prepared with and without the use of organic solvents showed that the nano-
C60 prepared without the aid of polar organic solvents not only showed no toxicity to 
rodents but actually protected the animals' liver from free radical damage.26 Our own 
findings regarding the toxicity of Baa and Baa peptides to human epidermal keratinocytes 
(HEK cells) showed that at concentrations less than 40 J.lg.mL"1 and 25 J.lg.mL-1 
respectively, no toxic response was observed.27 The logical conclusion from these various 
reports is that any C6o derivative intended for biological applications should be evaluated 
for toxicity and the data interpreted by experienced toxicologists. 
Bridging the gap between the biological and chemical worlds, nanoparticles such 
as C6o functionalized with biomolecules have the potential to revolutionize pharmacology 
and medicinal chemistry creating a new multidisciplinary approach to fighting disease. 
Chemists, inspired by the efficiency of the biological world, are arming themselves with 
a new arsenal of weapons to battle pandemics such as HIV. Through the intelligent 
design of a new class of pharmacophores, goals such as localized drug delivery and 
membrane penetration may be attainable. 
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Chapter 1 
Ducky-Amino Acid Acylation of pdCpA 
Introduction 
Marizio Prato was the first to prepare fullero-amino acids and later was the first to 
use the synthetic amino acids in the preparation of fullero-peptides through solid phase 
peptide synthesis (SPPS). 1a,b He recognized that the novel structure of C60 in conjunction 
with an amino acid moiety may provide unique opportunities to interact with the 
biological world through both its shape and scale. Since that time, many others have 
investigated C6o amino acids and peptides for their membranotropic, 24 antioxidant, 5 and 
antimicrobial6 properties. C6o peptides have also shown promise as enzyme inhibitors 
including HIV-1 protease and nitric oxide synthase.7 Currently, fullerene peptides are 
prepared by solid phase peptide synthesis (SPPS); however, this technique is inherently 
problematic for the incorporation of fullerene amino acids into a peptide sequence. 
During SPPS, hydrophobic resin beads immobilize a growing peptide chain onto 
the bead's surface so excess reagents and byproducts may be filtered away eliminating 
intermediate purification steps. Reagents are all used in large excess to drive the reaction 
yields to near 100%. Fullerene amino acids, with a large hydrophobic surface, 
irreversibly adsorb onto the bead surface (Figure 1.1 ). The dark color cannot be removed 
from the beads even after repeated cleavage reactions and many rinses. The irreversible 
adsorption results in less recovery of the fullerene amino acid starting material from the 
three to five time excess required for SPPS. Given the challenge of synthesizing and 
purifying C6o amino acids at a large scale, a more efficient procedure is needed. 
In our search for a highly efficient reaction system, the most logical starting point 
lies in the biological world. The challenge is to find a way to exploit it. A cell produces 
peptides and proteins through an organelle called the ribosome. The ribosome is a large 
quaternary protein that reads the code within mRNA to make specific protein sequences. 
15 
The ribosome pieces together proteins based on the genetic information translated from 
the messenger RNA (mRNA). The mRNA contains a three base sequence called a codon 
that complementarily encodes for a specific amino acid carried by the transfer RNA 
(tRNA). In addition to its amino acid cargo, the tRNA's second important part is its 
anticodon (Figure 1.2 a). The anticodon is recognized through complementary hydrogen 
bonding of nitrogenous base pairs with the mRNA and told to drop off its amino acid 
cargo to become the next link in the growing peptide chain (Figure 1.2 b). 8 
(a) (b) 
Figure 1.1. Solid phase peptide synthesis resin beads (a) before and (b) after reaction 
with Baa. The beads in vial (b) have been cleaved and rinsed multiple times. 
There are 61 three base codons corresponding to the 20 common amino acids in 
addition to three nonsense or stop codons that do not correlate to any amino acid. Instead, 
the nonsense or stop codons tell the ribosome to terminate the growing peptide chain. 10 
Eventually researchers realized they could hijack the ribosome and essentially trick it into 
making peptides with unnatural amino acids through the use of these nonsense codons. 
The field became known as non-sense suppression referring to the use of nonsense 
codons and suppressor tRNAs, which are responsible for recognizing nonsense codons. 10 
16 
(a) : 0 
3' : II 
· --.- -C-CHR- Amtno ac1d 
--- I 
NH ) Ester bond 
• 5' 
cceptor arm 
T'VC arm tRNA molecule 
Anticodon 
Figure 1.2. The tRNA molecule showing (a) the amino acid cargo and anti-codon and 
(b) the role of the ribosome, mRNA and tRNA in protein biosynthesis. 8· 9 
Hecht, 11 Chamberlin, 12 and Shultz 13 were pioneers in the work of nonsense 
suppression and site-directed mutagenesis. Hecht's group used a truncated suppressor 
tRNA, with the last two nucleotides cut off, specifically the phospho-cytidine-phospho-
adenosine subunit, pCpA. A nucleotide is a subunit of RNA that includes a phosphate 
group, a ribose sugar ring, and a nitrogenous base, giving it its name (Figure 1.3, shows 
phospoadenosine or pA). The structure of DNA is made of a deoxyribose sugar ring and 
differs only at the 2' position where a hydrogen replaces the hydroxyl group. Hecht's 
methodology, utilizing the dinucleotide pCpA (Figure 1.4), was synthetically simplified 
by Shultz with the substitution of deoxycytidine rather than cytidine as one of the 
nucleoside subunits creating the hybrid dinucleotide, pdCpA, without sacrificing function 
(Figure 1.3). 13 The amino acylated pdCpA (pdCpA-aa), is then enzymatically ligated to 
the truncated tRNA and fed into the ribosome for peptide biosynthesis. Over 50 unnatural 
amino acids have been added to the genetic code through this technique. 10 
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purines 
NH2 ] 
o-! ,. ~:CJ :..trogenoos 
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adenine guanine 
pyrimidines 
nucleoside 
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~~ 0 0 CNH YNH 
NAO NAO NA.O 
H H H 
cytosine uracil thymine 
Figure 1.3. The left side shows the structure of the nucleotide phosphoadenosine (pA), 
the 2', 3 ', and 5' positions are labeled. The five nitrogenous bases found in RNA and 
DNA are shown on the right. 
Figure 1.4. Dinucleotide structure composed of phosphates, sugar rings and nitrogenous 
bases, cytosine (top) and adenine. The compound is called pCpA when R = OH, and 
pdCpA when R = H. 
Despite the laborious nature and ultimately moderate yield of synthesizing 
pdCpA-aa, and then enzymatically ligating it to a truncated tRNA, it remains a widely 
used method of incorporating unnatural amino acids through the ribosome mediated 
18 
pathway. 14 Some advancements have been made since the early days of this work to 
improve the yield of the final product, pdCpA-aa, and to simplify the synthesis. 15 In our 
ongoing effort to find efficient ways to incorporate fullerene amino acids into peptide 
sequences, we decided to explore this biosynthetic pathway with our previously reported 
Bucky amino acid (Baa). 
Fullerene amino acids capable of forming peptide bonds have been prepared by 
many methods. ?b Our laboratory has utilized a Diels-Alder addition of 
trimethylsiloxybutadiene to the fullerene cage to form a bucky ketone intermediate with a 
convenient handle for functionalization (Scheme 1.1 ). A condensation reaction with 
Fmoc-Phe( 4-NH2)-0H yielded an imine linkage to C6o which was subsequently reduced 
by a BH3 · THF complex. The result is an extremely stable fullerene amino acid (Baa, 
Scheme 1.1). 16 
toluene reflux 
12 h on silica column 
~OH NN H~'Fmoc 
H 
Fmoc-Baa 
THF·BH3 
toluene, -78 °C 
bucky ketone 
toluene reflux, I 
TsOH cat., 24 hr 
~OH 
,..N__v H~'Fmoc 
Scheme 1.1. Synthesis of fullerene amino acid Fmoc-Baa through Diels-Alder addition 
intermediate bucky ketone. 
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Results and Discussion 
The acylation of a hybrid dinucleotide, pdCpA, with the fullerene amino acid, Baa 
was investigated. The unprotected hybrid dinucleotide, pdCpA (Figure 1.4), and the 
fullerene amino acid (Baa) were synthesized by reported literature methods. 15,16 The next 
and final step is amino-acylation the 2' or 3' hydroxyl of the sugar ring. Previous reports 
use an "activated" amino acid in the form of a cyanomethyl ester to limit nitrogen 
acylation of the nitrogenous bases.l3b The challenges we are facing are two-fold: 1) 
pdCpA is extremely hydrophillic with three negative charges, while Baa is hydrophobic, 
and 2) the presence of the fullerene moiety sterically hinders the reaction altogether. 
In our initial investigation two different approaches were used to bring the 
hydrophillic pdCpA and hydrophobic Baa into contact with each other. The first attempt 
utilized a cationic surfactant to exploit the inherent properties of each reactant through 
the formation of positively charged micelles in solution (Scheme 1.2).17 The goal was to 
sequester the negatively charged pdCpA on the surface of the micelle while the 
hydrophobic Baa resides on the interior of the micelle. The increased local concentration 
of each component around and in the micelle should lead to acylation of pdCpA. No 
products were ever observed by this synthesis method and, in fact, in most cases the only 
result was hydrolysis of the cyanomethyl ester. 
We next we tried the traditional approach of solubilizing pdCpA in 
dimethylformamide (DMF) by cloaking the negative charges with tetra-butyl ammonium 
(TBA) ions through ion exchange. 13 While both reactants were soluble in DMF, through 
this method no reaction products were observed after multiple attempts (Scheme 1.2). 
In an attempt to achieve oxygen acylation in high yield, several coupling 
strategies, including carbodiimides and perfluorophenyl esters, were considered. In a 
scheme utilizing coupling reagents the free amines must be protected (phosphates are 
shielded as TBA salts), whereas in published methods nitrogen acylation was limited by 
using a cyanomethylester of the amino acid. 13 Given that Hecht has shown previously 
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that tandemly activated suppressor tRNAs, made by his-amino acylation of pdCpA, are 
capable of participating in protein synthesis, we do not need to concern ourselves with 
diacylation. 18 However, the use of a deoxyribose dinucleotide may be a plausible way of 
eliminating the possibility of di-acylation, although, as yet, no one has attempted 
ribosome mediated biosynthesis with an entirely deoxyribose dinucleotide. Overall, 
considering the steric hinderance that has prevented the acylation of the nucleotide with 
Baa, it is unlikely that diacylation of the diol would occur. 
CTACI.buffer 
................ 
toluene, 37 "C 
DMF.r1,24hr 
................ 
(Bu4N+ )3 pdCpA 
(1.1) 
Scheme 1.2. Presented above are the unsuccessful coupling attempts using an activated 
Baa cyanomethyl ester, 1.1, and pdCpA. The first strategy used a cationic micelle formed 
in solution. The second method used the TBA salt of pdCpA to enable DMF solublity. 
Neither method was success. 
Before beginning the time consuming process of protecting already synthesized 
materials with the appropriate protecting groups, we needed a proof of concept that a 
coupling reagent would be effective in regards to the acylation of pdCpA. We utilized a 
diisopropylcarbodiimide (DIC) coupling reagent in conjunction with our protected amino 
acid, Baa, and pdCpA (Scheme 1.3). We investigated both Fmoc-Baa and the less bulky 
Boc-Baa through this method. After multiple attempts with DIC, some product (M + Na 
+ H mlz 1815.49, calcd. m/z 1815.26) was detected by MALDI MS from the crude 
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reaction mixture. However, after analysis by analytical HPLC none of the collected 
fractions with absorbance at 330 nm, indicating the presence of C60, proved to be the 
correct mass to charge ratio (mlz) by MALDI MS. Since we were unable to isolate our 
compound of interest, there was no way to determine whether oxygen or nitrogen 
acylation had occurred. In all subsequent attempts not even acylation of the free amines 
was observed, which was expected at least to some degree. 
NH2 
o c1 ·o-P-o~N 0 NH2 
6· N~N 
~ J. . .J ·o-~-o"1--0._) w OIC, HOBt, OMF v OHO. 
rt,5hr H y 0 """""~ 
FMOC,~~ 
(1.2) 
Scheme 1.3. DIC coupling of Baa to the TBA salt of pdCpA to make pdCpA-Fmoc-Baa 
(1.2). 
Given that all published methods and even our more aggressive coupling strategy 
had failed to acylate pdCpA, the reactivity of the dinucleotide diols needed to be 
confirmed. In this regard, a perfluorophenyl ester of Fmoc-glycine (Fmoc-Gly-OPfp) was 
coupled to pdCpA in anhydrous DMF (Scheme 1.4). As expected, mono- and di-
acylation products were observed by HPLC and MALDI MS (Figure 1.5). To confirm we 
had at least some oxygen acylation, a portion of the reaction mixture was shaken with a 
5% bicarb solution thereby cleaving the ester linkages but leaving amide bonds intact. 
The change in the chromatograms before and after the bicarb treatment confirmed that a 
large degree of esterfication had occurred (Figure 1.5). It is worth noting that no 
triacylated products were observed in the mass spectrum of the crude reaction mixture 
and very little diacylated product remained after the bicarb treatment. After witnessing 
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the ease with which the acylation with an unhindered amino acid should occur with 
coupling reagents, it became clear that we would have to find some other way of bringing 
these two molecules together. 
an. DMF, rt 3 hr 
NH2 
_,.h N 
0 Q __ J, 
·o-P·O~o N 0 NH2 
o· C:::) N~N 
o < JL J 
·o -P-Ot__...o ....._N N 
0 ~ 
Fmoc-Giy O OH 
Fmoc-Giy-NH 
_,.hN 
0 t_J, 
·o- P-OI~O..._ N 0 NH2 
o· ~ N~N 
o < JL J 
·o-6-olC:J N 
OHOH 
monoacylated products (1.3) 
diacylated products (1-4) 
Scheme 1.4. Coupling of hybrid dinucleotide pdCpA with Fmoc-Gly-OPfp and the 
possible products of the reaction. Products were characterized by MALDI MS and HPLC 
to determine if acylation had occured. 
50 
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Figure 1.5. Presented above are the HPLC chromatograms (blue is before bicarb 
treatment and pink is after) of the reaction mixture showing major and minor products 
from the coupling between pdCpA and Fmoc-Gly-OPfp. 
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Conclusions 
Our investigation into the acylation pdCpA with a fullerene amino acid led us to 
the conclusion that our fullerene amino acid, Baa, was entirely too hindered to react with 
pdCpA. Even under rigorous coupling conditions with a DIC coupling reagent, very little, 
if any, product was observed. However, pdCpA is easily acylated with other less hindered 
amino acids as we have demonstrated with a perfluorphenyl ester of glycine. Based on 
our results thus far we have decided to pursue alternate methods for acylation of pdCpA 
with fullerene amino acids. There are two possibilities: 1) to attach C6o as the final step 
after the acylation of pdCpA or 2) utilize a fullerene amino acid with a more flexible side 
chain such as lysine. Both of these strategies require a new route fullerene derivatized 
amino acids. 
Experimental 
Nucleoside precursors and phosphoramidte coupling reagents were purchased 
from Chem-Impex International, Inc., unless otherwise specified, and used without 
further purification. C6o fullerene (99.5% purity) was purchased from MER Corp. and 
was purified chromatographically with toluene prior to use to remove trace oxides. 
All other chemicals and reagents were purchased from Sigma-Aldrich. All solvents 
were dried and distilled prior to use using standard techniques unless otherwise 
specified. Products were purified by flash column chromatography on silica gel (230-
400 mesh). 
1H NMR spectra were recorded on Bruker Avance 400 and 500 MHz 
spectrometers. MALDI measurments were performed on Bruker Reflex or Autoflex 
with TOF detection. DCTB (2-[(2E)-3-(4-tert-butylphenyl)-2-methylprop-2-
enylidene ]malononitrile) and elemental sulfur were used as the matrices to 
characterize fullerene derivatives by MALDI/TOF (negative mode, M·- ionization). a-
Cyano-4-hydroxycinnamic acid (CHCA) was used as the MALDI matrix for all other 
24 
compounds. UV-Vis spectra were recorded on a Varian Cary 5000 spectrometer. High 
performance liquid chromatography (HPLC) was performed on a Varian ProStar 
instrument using a Varian C1s column (150 x 4.6 mm) for reaction monitoring and a 
Varian Dynamax C1s column (250 x 21.6 mm) for purification. 
The fullerene amino acid, Baa, 16 and the hybrid dinucleotide, pdCpA, 15 were 
synthesized according to literature methods. The phosphates of pdCpA were shielded 
through ion exchange with tetra-butyl ammonium (TBA) ions. The resin was prepared by 
packing a column with a cationic exchange resin (Dowex 50Wx8, 200 mesh) and 
flushing it with tetra-butylammonium hydroxide (TBA + ·oH, 1%, ~ 250 mL) until the 
eluent was basic. Next the column was flushed with deionized water until the eluent was 
neutral again. The nucleotide was stirred with the exchanged resin as an aqueous mixture 
( ~ 5 mL resin/1 00 mg pdCpA, 5 - 10 min) in a round bottom flask in an ice bath, after 
which the resin was filtered out. The ion exchanged nucleotide [ (B14N)3 ·pdCpA] was 
lyophilized to dryness and stored as a fluffy, white powder. Stock nucleotide solutions 
(50- 60 mM) were prepared in anhydrous dimethylformamide (an. DMF) as needed. 1H 
NMR showed a TBA to pdCpA ratio of 3.3 to 1. Concentrations of the stock solutions 
were determined by UV (E260nm 23,000 cm"1M"1). 
Fmoc-Baa-OCH2CN (1.1). Fmoc-Baa (125 mg, 0.1062 mmols) and 
triethylamine (TEA, 29.6 J.LL, 0.2125 mmols) were dissolved in DMF (50 mL). The Baa 
solution was added by syringe to an evacuated 100 mL round bottom flask fit with a stir 
bar and septa. Chloroacetonitrile (Cl-CH2-CN, 20.2J.LL, 0.3189 mmols) was added to the 
round bottom by syringe and the reaction was stirred under an Ar atmosphere. After 24 h 
the reaction mixture was diluted with dichlormethane (DCM, 150 mL), washed with 
sodium bisulfate (0.5 M, 150 mL, 2x) and then brine (150 mL, 1x). The organic phase 
was then dried over sodium sulfate, filtered, and concentrated under reduced pressure. 
The concentrate was then applied to a column of silica gel and the cyanomethylester of 
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Baa was eluted with 1:1 ethyl acetate:hexane. Yield: 116.2 mg, 90%. 1H NMR (400 
MHz, CDCh): <> 7.69 (2H, m), 7.50 (2H, m), 7.33 (2H, m), 7.25 (3H, m), 6.97 [2H, d, 
J(H-H) = 7.3 Hz), 6.73 [2H, d, J(H-H) = 7.76 Hz], 5.15 (1H, s), 4.85 (1H, m), 4.76 [2H, 
d, J(H-H) = 15.50 Hz), 4.66 [2H, d, J(H-H) = 15.50 Hz), 4.40 (1H, m), 4.28 (1H, m), 
4.13 (1H, m), 3.73 (2H, m), 3.54 (3H, m), 3.28 (1H, m), 3.02 (2H, m), 2.52 (1H, m). 
MALDI mlz (calcd.): (M·)" 1215.26, (1215.22). 
Carbodiimide coupling of pdCpA and Fmoc-Baa (1.2). To a 1 mL conical vial 
with a spin vane was added 1-hyroxybenzotriazole hydrate (HOBt hydrate, 1.1 mg, 0.008 
mmols), (Bt4N)3·pdCpA stock solution (100 J..I.L, 55 mM, 0.0055 mmols), Fmoc-Baa 
stock solution (113 J.!L, 58 mM, 0.0066 mmols) both prepared in an. DMF, and N,N'-
diisopropylcarbodiimide (DIC, 1.1 J.!L, 0.00715 mmols). The reaction was allowed to stir 
for 5 h after which 2 J..I.L of the reaction mixture was diluted to 50 J..I.L with 1: 1 acetonitrile 
(MeCN):0.1% TFA and centrifuged (4400 RPM, 2 min.). Analytical HPLC [0.1% aq. 
TFA (100- 0%) and acetonitrile (0- 100%) over 50 min., detection at 260 nm and 330 
nm] showed only one fraction with absorbance at both 315 and 260 nm which was found 
to be HOBt. No product was isolated. MALDI mlz (calcd.): (M + H + Na)" 1815.49, 
(1815.26). 
pdCpA-Fmoc-Gly (1.3) and pdCpA-(Fmoc-Gly)l (1.4) (Bt4N)rpdCpA (1 00 
J..I.L, 55 mM in an. DMF, 0.0055 mmols) was added to a perfluorophenyl ester of Fmoc-
glycine solution in DMF (100 J.!L, 55 mM in an. DMF, 0.0055 mmols) in a conical vial fit 
with a spin vane. The reaction was stirred at room temperature under an Ar atmosphere 
for 3 h after which 2 J..I.L of the reaction mixture was diluted to 50 J..I.L with 1: 1 acetonitrile 
(MeCN):0.1% TFA and centrifuged (4400 RPM, 2 min.). Analytical HPLC [0.1% aq. 
TFA (100- 0%) and acetonitrile (0- 100%) over 50 min., detection at 214 nm and 260 
nm] revealed two major products and almost no starting materials remaining. Appropriate 
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fractions were pooled and characterized by MALDI MS using a CHCA matrix. MALDI 
rn/z (calcd.): (M + 2H)" mono-acylated 915.16 (914.85), di-acylated 1194.58 (1193.94). 
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Chapter 2 
C60 Amino Acids through Dipolar Addition 
Introduction 
Whether for its anti-oxidant, anti-HIV, anti-cancer, or membranotropic properties, 
fullerenes, specifically water soluble fullerene derivatives, have captured the imagination 
of researchers since their discovery in 1985.1 As an approximately 1 nm perfect carbon 
sphere, C60's size, shape, and hydrophobicity afford it the unique opportunity to interact 
with the biomolecular world. It was inevitable that fullerenes would eventually find 
themselves incorporated into biologically relevant molecules such as lipids, saccharides, 
and oligonucleotides. 2 But perhaps the most ubiquitous use of fullerenes in the 
biochemical world is as an amino acid, the most basic building block of life. 
Our reasons for developing a new fullerene amino acid are three-fold. First, we 
need a way to attach C60 as the final step to eliminate the steric hinderance preventing the 
acylation of our hybrid dinucleotide, pdCpA, as discussed in Chapter 1. Second, ideally 
the method is general enough for the synthesis of a variety of fullerene amino acids, both 
alkyl and aryl. In this regard, the yield of our flexible fullero-Lys derivative must be 
improved to move forward with future applications in HIV -1 PR and carbonic anhydrase 
inhibition.3 Lastly, the synthesis needs to be a fast, good yield method occurring under 
very mild conditions. 
A variety of synthesis methods exist to make fullerene amino acids; almost all 
utilize cycloadditions to the fullerene core. The first fullerene derivative with a 
convenient handle for "peptide functionalization" was prepared by Prato in 1993 through 
carbene addition, generated in situ with diazomethane, to the fullerene cage. This paved 
the way for other methods utilizing diazocompounds to generate carbenes.4 Another 
method for producing a useful fullerene handle is the Diels-Alder addition of a butadiene 
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derivative to fullerene creating a Bucky-ketone intermediate. 5 The original report then 
reduced the ketone to a hydroxyl and used a dicyclohexyl carbodiimide (DCC) coupling 
to ligate the functionalized fullerene to a peptide. A similar route was reported by our lab 
utilizing the Bucky-ketone intermediate in a condensation reaction with an amino 
derivatized natural amino acid then reduced with a BH3 ·THF complex, Scheme 2.1. 6 This 
method produces very stable fullerene amino acids in good yield (~50%); however, it 
suffers from long preparation times, about two weeks, even in experienced hands. 
toluene reflux 
+ }OSiMe3 12 h on silica column 
~OH ~~ HN,Boc 
Boc-Baa 
THF-BH3 
toluene. -78 °C 
+ 
0 
bucky ketone 
toluene reflux, l 
TsOH cat., 24 hr 
~OH ~N~ HN,Boc 
Scheme 2.1. Original Bucky-amino acid (Baa) synthesis including the Bucky ketone 
intermediate. 
Perhaps the most widely used method of making fullerene amino acids is the 
addition of azomethine ylides to the fullerene cage, also called the Prato reaction. 
Initially, Prato's method produced a fulleropyrolidine derivative which was subsequently 
condensed with a protected glutamic acid residue. 7 The original method is a multistep 
synthesis producing several intermediates, which must be purified, before reaching the 
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ultimate goal, a fullerene derivatized amino acid able to be incorporated to a peptide 
sequence through solid phase peptide synthesis (SPPS). Later Prato improved the 
synthesis to create fulleroproline, Fpr, the largest non-natural amino acid to date, and the 
first example of a C60-substituted fulleryl-amino acid. 8 However, the synthesis yields a 
racemic mixture of cis-trans isomers which must be purified on a chiral column before 
use in solid phase peptide synthesis (Figure 2.1 ). 
cis trans 
Figure 2.1. Cis-trans equilibrium about the tertiary amide.8 
The final and possibly the most efficient method for the production of fullerene 
amino acids is through cyclopropanation, first reported by Bingle9 and improved to a one-
pot synthesis by Camps and Hirsch. 10 The Bingle reaction is one of the most efficient 
with yields around 50% but utilizes DBU that our nucleotide, pdCpA, cannot tolerate. 
Since our ultimate goal is to find a simple, fast preparation for fullerene amino acids 
occurring under very mild conditions, none of these methods are ideal for our purposes. 
Several different cycloaddition reactions to C6o have been discussed including 
[2+ 1] cyclopropanation and car bene additions, [3+ 2] ylide addition, and finally a [ 4+ 2] 
Diels-Alder addition. None of them are acceptable for our purposes due to the conditions 
employed, specialized purification, or the time required. We are in need of a simple, 
mild, high-yield method of incorporating C60 onto the R side chain of an amino acid as 
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the final step in a synthesis. For these reasons, we began to explore the addition of 1, 3-
dipoles to c60· 
Prato showed that azides react with C6o in a similar manner as other 1, 3 dipoles 
to form aza-fulleroids and aziridino fullerenes. 11 The dipolar addition to the fullerene 
cage is a simple method for decorating the fullerene cage with a yield consistently around 
30% for the mono-addition products. The reaction conditions can be manipulated to 
achieve either a 6,6-closed aziridino structure by nitrene addition or a 5,6-open aza-
fulleroid structure by azide addition and N2 extrusion (Figure 2.2). 12' 12 
a b 
I 
N 
Figure 2.2. The structural unit of (a) 6,6-closed aziridino fullerene and (b) 5,6-open aza-
fulleroid. 
Our new approach to a fullerene derivatized amino acid can be completed in three 
days, including synthesis of starting materials (2.2 - 2.4 and 2.8 - 2.10, Scheme 2.2) and 
chromatographic purification, with an ~ 30% yield of the protected mono adduct, 
Phe(aza/aziridino-C60) (2.5 - 2.7, Scheme 2.2). This methodology was also used 
successfully to prepare a protected Lys(aza/aziridino-C6o) derivative (2.11 - 2.13, Figure 
2.3). 
TMS-CI 
MeOH, 24h 
ISA·CIH 
MeOH/MeCN, rt, 
ZnCI2 
H 0 
Fm~N~OMe 
Np 
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(2. 1) Fmoc-Phe( 4-NH2)-0Me (2.2) Fmoc-Phe(4-N3)-0Me 
(2.2), (2.3), or (2.4) 
R1 = Boc or Fmoc 
Cso.ODCB 
180°C,4h 
a 
ISA·HCI 
MeOH/MeCN, rt, 
ZnCiz 
b 
(2.3) Phe(4-N3)-0H, R1 = Fmoc 
(2.4) Boc-Phe(4-N3)-0H, R1=Boc 
(2.5a) Phe(4-aza-C60), R1 = Fmoc, R2 = Me 
(2.5b) Phe(4-aziridino-C60) , R1 = Fmoc, R2 = Me 
(2.6a) Phe(4-aza-C60), R1 = Fmoc, R2 = H 
(2.6b) Phe(4-aza-C60), R1 = Fmoc, R2 = H 
(2.7a) Phe(4-aza-C60), R1 = Boc, R2 = H 
(2.7b) Phe(4-aziridino-C60), R1 = Boc, R2 = H 
Scheme 2.2. The synthesis of phenylalanine azido starting materials and aza and 
aziridino fullerene amino acids. 
(2.8) Boc-Lys(N3)-0H 
a b 
(2.9) Boc-Lys{N3), R1 = Me 
(2.1 0) Boc-Lys(N3), R1 = 1Bu 
(2.11a) Boc-Lys(aza-C60), R1 =Me 
(2.11b) Boc-Lys(aziridino-C60), R1 =Me 
(2.12a) Boc-Lys(aza-C60), R1 = 1Bu 
(2.12b) Boc-Lys(aziridino-G60), R1 = 1Bu 
(2.13a) Boc-Lys(aza-C60), R1 = H 
(2.13b) Boc-Lys(aziridino-C60), R1 = H 
Figure 2.3. Azido-Lys starting materials and Boc-Lys(aza/aziridino-C60) derivatives. 
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Results and Discussion 
We have investigated the use of protected azido-amino acids in the synthesis of 
stable fullerene amino acids. At the beginning of the use of this methodology, we were 
aware that we would potentially generate two isomers: the 5,6-open aza-fulleroid product 
and the 6,6-closed aziridino fullerene product (Figure 2.2). What was not immediately 
obvious was which isomer might be more suited for our future applications. The kinetic 
aza product (5,6-open) is formed through a [3+2] azide addition to a 6,6 bond of C60. A 
rearrangement follows in which the leaving N2 molecule prevents the generated nitrene 
from re-adding at the 6,6 position. Instead the nitrene adds to a pentagon hexagon single 
bond generating the 5,6-open aza isomer. Under a different set of conditions the aziridino 
isomer is formed when the nitrene is generated before the addition to the fullerene core 
by thermolysis, photolysis or electrolysis. 13 The nitrene adds to a hexagon-hexagon 
double bond forming a 6,6-closed aziridino isomer. We employed a variety of conditions 
in an effort to control isomer formation, increase yields, and shorten preparation times. 
Changes to the solvent system and the temperature resulted in the most significant 
yield increases. Initially, C6o was refluxed in toluene for solubility but a co-solvent was 
used to introduce the amino acid. C6o has been shown to be more easily reduced in THF 
solutions and when this was used as the co-solvent the yield was improved. The 
temperature of the refluxing toluene/C60 solution was consistently around 109 °C and the 
survival of the azido functional group was confirmed throughout the reaction by thin film 
IR (vasym = 2100 cm-1).3 Eventually, it was discovered that both reactants were readily 
soluble in arrha-dichlorobenzene (ODCB) and, in this solvent, the reaction was complete 
within 24 hours (at 100 °C) with less formation of the multiple addition products. 
In an attempt to push the reaction products more to the 6,6-closed isomer, the 
reaction was performed at 180 °C (refluxing ODCB) which should be sufficient to 
decompose the azide to a nitrene. Under these conditions the reaction was usually 
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complete within four hours (or until the disappearance of the azido amino acid by TLC). 
Interestingly, under these conditions, the aziridino product was still not formed to an 
appreciable degree and the total yield of the mono product was consistently around 30% 
regardless of the temperature. The thermodynamic aziridino product was isolated only 
when the reaction was performed at low temperature for more than 24 hours. However, 
allowing the thermodynamic product to form meant the formation of many more multiple 
addition products in the course of the reaction. Further attempts to generate the closed 
isomer were limited to post-purification experiments and will be discussed later. 
Table 2.1. Reaction conditions for C6o phenylalanine derivatives. 
Reaction Reaction Isolated Isolated 
time temperature Solvents Rt. R2 yield, open yield, closed 
(hrs) (oC) (%) (%) 
120 110 toluene/THF Fmoc, OH 14 
72 110 toluene/THF Fmoc, OH 20 13 
24 110 toluene/THF Boc, OH 19 8 
24 110 ODCB Fmoc, OH 25 2 
4 180 ODCB Fmoc,OH 32 
Table 2.1 shows the reaction variables including reaction time, temperature, 
and solvent composition and includes the isolated yield of the mono open and closed 
products for the phenylalanine derivatives. In addition to the mono fullerene adduct, 
multiple addition products (up to hexakis adducts) are also formed as reaction time 
increases. Depending on the conditions of the reaction, the formation of multiple 
addition products may be limited. The multiple addition products were usually not 
isolated and may be limited by monitoring with reverse phase HPLC or adjusting the 
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reaction conditions. The reactions were usually stopped when tris products formed. 
One of the goals of this synthesis is to create a general method for the preparation 
of fullerene amino acids and to improve the yield of our fullero-Lys derivatives. In this 
regard, the optimal reaction time and temperature were substrate dependant, either alkyl 
or aryl and in most cases the reaction was stopped when the tris-adducts began forming 
(monitored by HPLC). The temperature of the reactions were usually maintained around 
90-100 ac and the survival of the azido functional group was confirmed by thin film IR 
(vasym = 2100 cm-1). 10 Azido-lysine (alkyl) decomposes around 90 °C, resulting in 
undesirable reaction products (not isolated), but is avoidable by protection of the C-
terminus. However, when the temperature was maintained around 60 °C, no C-terminus 
protection was required and no undesirable reactions occurred. 
Many more multiple addition products were formed from the aryl azides relative 
to the alkyl azides (by HPLC) under the same reaction conditions and the yield for the 
mono adduct was consistently lower for Lys than for Phe. For Phe derivatives, increasing 
the reaction time beyond 24 hrs did not improve the yield of the mono-adduct and 
consumed a great deal more C6o in the form of multiple addition products. For 2.11, 2.12, 
and 2.13 the reaction proceeded much more slowly due to the temperature difference. 
These reactions typically went more than 72 hours before formation of the tris products. 
The choice in N a protecting group seemed to have little change on the yield and 
was dependent upon the future applications of the fullerene amino acid. However, it must 
be noted that, the aza-fullerene linkage is slightly acid labile so precautions must be taken 
to protect the linkage during acidic deprotection by lowering the concentration of 
trifluoroacetic acid (TF A, 25% in dry DCM) utilized. Piperidine deprotection of Fmoc 
protected fullerene compounds has been shown to form adducts with the fullerene cage 
making purification very difficult. 14 While we did not observe any formation of adducts 
by MALDI-ToF, the Boc approach proved more facile and is consistent with our current 
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SPPS strategy. As discussed previously, the azido-Lys starting materials had to be both 
amino and carboxy protected for the reaction to occur at temperatures over 60 °C 
otherwise a complicated mixture of products formed. The reaction conditions and yields 
of the fullero-Lys derivatives are given in Table 2.2. 
Table 2.2. Reaction conditions for the synthesis of aza/aziridino C60 lysine derivatives. 
Reaction Reaction Isolated 
time temperature Solvents R1. R2 yield 
(hrs) ( oc) (%) 
72 60 Toluene/THF Boc, OMe 13 
72 100 Toluene/THF Boc, OMe 22 
72 100 Toluene/THF Boc, OH NR 
72 100 Toluene/THF Boc, OtBu 11 
72 60 ODCB Boc, OH 19 
The pure isomers are easily separated by filtration through a large silica plug, 
eluting with toluene to remove un-reacted C60, followed by a stepped gradient to elute 
each isomer. Two different color bands with similar Rrs of the same mass to charge 
ratio (m/z) as our desired product were isolated. The purification of the aza and 
aziridino derivatives is a significant improvement over Baa, in both time and solvent 
consumption. In addition, all of the remaining unreacted C60 (~70%) is recovered 
Detailed purification notes are included in the Experimental section. 
Characterization of Isomers. The UV -visible absorption spectra of each 
fullerene amino acid in chloroform show maxima at approximately 260 and 330 nm, 
consistent with presence of the C60 moiety. Aziridino fullerenes (2.5b- 2.7b, and 2.1lb-
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2.13b) exhibit an additional absorption around 420 nm. 15 Figure 2.4 shows the UV-
visible spectra of the lysine derivatives in comparison with pristine c60· In addition to the 
conserved peaks due to the C60 core, the spectra of 2.13b shows a small peak at 423 nm 
(see Figure 2.4, inset), confirming the 6,6-closed aziridino-fullerene structure 
determination. The spectra of 2.13a shows no similar absorption. The Amax at 327 nm (£ 
40,000) was used to determine the concentration of fullerene amino acids in solution. The 
colors of the aza derivatives are blue/purple, while the aziridino compounds are either 
amber (2.Sb - 2.7b) or pink (2.11b- 2.13b). 
<1.> 
(.)--
c: (/) 
('0:0: 
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Figure 2.4. UV absorption spectra of (a) Boc-aziridino-C6o-Lys (2.13b), (b) Boc-aza-C6o-
Lys (2.13a) and (c) C6o· 
Further confirmation of the aza versus aziridino structures was obtained from the 
electrochemical behavior as determined by cyclic voltammetry (Figure 2.3). CV 
measurements were made in a mixture of DMF/toluene (3:2) at room temperature with 
[Bu4N][BF4] as the electrolyte. C60 is known to be less easily reduced with each 
successive addition to its core. For C60 derivatives, the first electron transfer is shifted to 
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more negative potentials while maintaining the characteristic redo~ properties of pristine 
C6o-16 In this respect, Baa (6,6-closed) is consistent with other similar closed ring 
structures, with its first reduction occurring at -0.377 V (Table 2.3). In contrast, in the 
open ring structure of the aza-C60 derivatives (2.7a and 2.13a, Figure 2.3), only sp2 
hybridized carbons are present on the cage allowing these compounds to behave more 
like pristine C60 in their reductive ability under the specified conditions. 17 Table 2.3 
shows the detailed redox potential data for the aza and aziridino-fullerene derivatives 
relative to C60 and the previously reported Baa. 18 For C6o and the aza-fulleroid derivatives 
the first reduction occurs between -0.248 and -0.288 V. However, the closed ring 
structures with two sp3 C60 carbons do not undergo their first reduction until more 
negative potentials, cathodically shifted approximately 0.04 - 0.15 V relative to the aza-
fulleroid derivatives. 
10.00 
{c) {A Ji J 
8.00 r< {d) J ~!j 
6.00 {a) ~· /,./ f 
4.00 0fi:J / -_.,.. ~ I 
Current ;/ / 
(J..lA) _/' - / / 
I 
-500 -2000 
--:;~ 
\ 
'-
-6.00 
Potential (mV vs. Ag 1 AgCI) 
Figure 2.5. Cyclic voltammograms o! (a) Boc-aza-C6o-Phe (2.7a), (b) Boc-aza-C60-Lys 
(2.13a), (c) C60, and (d) Boc-aziridino-C6o-Lys (2.13b) in 0.1 M [TBA][BF4] in 
DMF/toluene (3:2) at room temperature. Scan rate, 100 mV.s-1. 
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Table 2.3. Selected cyclic voltammetry data for fullerene amino acids. a 
Compound Formal potential a, Ev2 Structure 
I II III IV 
C6o -0.247 -0.741 -1.327 c 
Boc-Baa -0.377 -0.847 -1.489 c 6,6-closed 
Boc-Lys(aziridino-C6o) (2.13b) -0.319 -0.792 b c 6,6-closed 
Boc-Lys(aza-C6o) (2.13a) -0.280 -0.892 b c 5,6-open 
Boc-Phe(4- aza-C6o) (2.7a) -0.270 -0.744 -1.318 -1.458 5,6-open 
a Formal potentials are calculated as averages of oxidation and reduction peak potentials. 
Potentials are given in volts vs. a reference electrode, AgiAgCl. b Third or c fourth 
reduction not observed. 
Closer inspection of the voltammogram data from the 5,6-open derivative (green 
line) revealed a fourth reduction peak that did not fit with the rest of the pattern (Table 
2.3). The first three reductions were spaced by an average of 0.55 V, whereas the fourth 
reduction occurs at -1.458 V, only 0.14 V from the third reduction peak. Previous reports 
have shown that methano-fulleroids can be electrochemically converted to the 6,6-closed 
isomer with a voltage of approximately -1.5 V .19 Based on this knowledge, we surmise 
that the 4th reduction peak actually represented the reduction of the 6,6-closed isomer that 
was generated in-situ and therefore we may be able to utilize this electrochemical isomer 
conversiOn. 
Isomer stability and conversion. It was not clear which isomer would be more 
stable or better suited for our applications. In addition, we need to determine whether the 
substituent adjacent to the aza/aziridino nitrogen (i.e. either aryl or alkyl) has an effect on 
the structure's stability. Fullerene and its derivatives are particularly sensitized to photo-
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decomposed to C6o and protected Phe(4-NH2) after several days with exposure to light 
and air. In the absence of light, no oxidation occurred indicating that the oxidation is 
photo-initiated. Over time, even under vacuum and in the dark, the aza-Phe derivatives 
slowly decompose. 
In contrast to the aza-Phe compounds, the aza-Lys derivative, in light and air, 
does not decompose readily, however oxidizes to a product 32 mass units higher than the 
M" ion. The acute oxygen sensitivity and subsequent ketolactam formation ( + 32 mass 
units) of alkyl aza-fulleroids is well documented in the literature.23 Figure 2.6 illustrates 
the structure of the ketolactam formed by the oxidation of an aza-C60 derivative. No such 
oxidation was observed for any of our aziridino (6,6-closed) products in analogous time 
periods. While the study of the aza-fulleroids was not abandoned, the oxidative stability 
of the aziridino isomers makes them more desirable as a pharmacophore. The closed 
product was also the more challenging of the two isomers synthetically. As a result, we 
focused our efforts on converting the aza-fulleroids to aziridino fullerenes through post 
synthesis methods such as electrolysis. 
Figure 2.6. Ketolactam formation as a result of oxidation of aza-C6o derivatives.23 
Several groups have demonstrated the conversion of the open product to the 
thermodynamically more stable closed product through photo-, thermo-, and 
electrochemical means.24 All efforts to convert the kinetic aza products to the 
thermodynamic aziridino products thermally, as a dry powder and in refluxing toluene or 
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ODCB (thoroughly dried and deoxygenated), failed. Refluxing either the Phe or Lys aza 
derivatives in ODCB caused the formation of an uncharacterized high mass, insoluble, 
brown precipitate after less than 24 hours. For both derivatives, thermal conversion by 
refluxing in toluene (120 h.) or as a dry powder (5 h. under an Ar atmosphere) had no 
effect. However, the fact that the closed products had been isolated from reactions that 
were allowed to proceed for more than 24 hours indicated that thermal conversion is a 
viable method. Further attempts to convert either derivative by electrolysis (ca. -1.5 V) 
and photolysis (300 nm) resulted only in oxidation and/or decomposition. 
Potential Toxicity. Given that the Phe(4-aza-C6o) and Lys(aza-C6o) are easier to 
prepare on a large scale, and therefore of much greater utility for subsequent studies as 
compared to Baa, it is important to ensure that the change in linkage unit does not alter 
the cellular toxicity significantly. The Boc-aza-Phe derivative was deprotected using 25% 
TFA as shown in Scheme 2.3. The toxic response of the deprotected Phe(aza-C6o) (2.14) 
was determined by MTT assay. Three different neuroblastoma cell lines (JF, SK-N-AS, 
and LAN-I) were used in the assay and compound 2.14 was used at concentrations from 
0.004 - 0.4 mgmL-1• No appreciable toxicity was observed for 2.14 at any of the tested 
concentrations after a 24 hour incubation period (Figure 2. 7). In previous studies Baa was 
shown to be toxic at concentrations over 40 j..l.g.mL-1 ?5 
2.7a 
25% TFA PO NH2 
I DCM,3h~ 
\:W 
2.14a 
Scheme 2.3. Deprotection ofBoc-Phe(4-aza-C6o) with trifluoroacetic acid. 
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Figure 2. 7. Graph depicting toxicological data obtained by incubating Phe( 4-aza-C60) 
(2.14) with various neuroblastoma cell lines. The toxicology experiments were 
performed by collaborators. 
Reactivity. To demonstrate the ability of the new fullerene amino acids to be 
incorporated into peptide sequences, 2.6a was coupled to tert-butyl ester of glycine (NH2-
Gly-OtBu). The reaction was carried out in 4: 1 DCM/DMF in the presence of HBTU and 
NEt3 in a sonication bath for 2 h (Scheme 2.4, 2.15). The dipeptide product was detected 
by MALDI (m/z M + 1 1234.11 , calcd. 1234.23) after 2 hours confirming the ability of 
the amino acid to form peptide bonds. 
Gly-01Bu. HBTU, TEA 
2.6a 
m/z 1120.1 
an . DMF, 2 h, Ar 
0 H 
'Bu01('WH N,Fmoc 
P I 
N ~ 
2.15 
m/z 1234.1 
Scheme 2.4. The reaction of 2.6a with a tert-butyl ester of glycine. 
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Conclusions 
In summary, we have reported a general route to fullerene derivatized amino 
acids through the dipolar addition of azido amino acids, both alkyl and aryl. The ease 
of this procedure, including purification, is evident over previously reported 
methods. 6 The newly reported C60 amino acids differ in their linkage to C6o, resulting 
in a 5,6-open, aza-fulleroid structure as the major product (85% of isolated yield). 
The substituent adjacent to the aza or aziridino nitrogen affects the compound's 
stability to oxidation and degradation. While the aziridino isomer proved the most 
stable for future applications we have been unable to synthesize it in appreciable 
amounts and will use thermal conversion to generate the closed isomer. While the aza 
derivatives are acutly sensitized to 0 2, the reaction does not occur in the dark and 
therefore they may still find some use as pharmacophores. The aza products tendancy 
to oxidize may be exploited in some applications, such as protein inhibition. In 
addition, we have demonstrated the coupling ability of the new fullerene amino acids 
indicating their ability for incorporation into a peptide sequence through SPPS. 
Experimental 
Protected amino acids were purchased from Chem-lmpex International, Inc., 
unless otherwise specified, and used without further purification. Fullerene (99.5% 
purity) was purchased from MER Corp. and was purified chromatographically with 
toluene prior to use to remove trace C6o oxides. All other chemicals and reagents were 
purchased from Sigma-Aldrich. All solvents were dried and distilled prior to use 
using standard techniques unless otherwise specified. When necessary, products were 
purified by flash column chromatography on silica gel (230 - 400 mesh). 1H NMR 
spectra were recorded on Bruker Avance 400 and 500 MHz spectrometers. MALDI 
MS measurments were performed on Bruker Reflex with TOF detection. DCTB {2-
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[(2E)-3-( 4-tert-butylphenyl)-2-methylprop-2-enylidene ]malononitrile} and elemental 
sulfur were used as the matrices to characterize all fullerene derivatives by 
MALDI/TOF (negative mode). UV-Vis spectra were recorded on a Varian Cary 5000 
spectrometer. Cyclic voltammetry data was recorded on CV -SOW voltammetric 
analyzer. 
General diazo-transfer reaction. Imidizole-sulfonyl-azide·HCl (ISAHCl) 26 was 
used as the diazotransfer reagent. Initially trifyl azide (TfN3) was investigated as the 
diazotransfer reagent and was prepared by literature methods.27 The concentration of the 
solution was determined by assuming complete conversion of the Tf20 starting material. 
Since TfN3 is slightly explosive, it cannot be dried down completely and therefore cannot 
be characterized completely. The ISA HCl was the superior reagent as it is crystalline, easily 
prepared on the gram scale, and has a long shelf life as opposed to trifyl azide. The subsequent 
diazo-transfer takes place with a divalent catalyst and a base at room temperature. The 
choice of catalyst and base were substrate dependant. 
An amino derivatized, Na-protected amino acid (1 eqiv.), ISAHCl, triethylamine 
(2 eqiv.) and 4 mole% ZnCh were dissolved in a solution of MeOH:MeCN (3:2) and 
stirred in the dark under N2 for 12 h. The mixture was concentrated then diluted with 
ethyl acetate and washed with AcOH (10%, 3 x, 200 mL) and brine (1 x, 200 mL), dried 
over MgS04, and concentrated under vacuum. Flash chromatography is necessary at the 
gram scale. Reaction progress was monitored by IR for the characteristic ISA·HCl stretch 
(approx. 2110 cm"1) to shift and the loss ofNH stretching absorbencies from the starting 
material. The reaction was shielded from the light at all times, including work-up, to 
prevent decomposition of the azide. 
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General C60 amino acid synthesis. C60 (1 equiv.) was vacuum dried for 45 min 
and ortho-dichlorobenzene (ODCB) was added by cannula. To this was added the Na-
protected, azido-amino acid (1 equiv.) with stirring. The temperature was maintained 
between 80 - 100 °C for the Phe derivatives and 60 - 70 °C for the Lys derivatives. The 
reaction was monitored by RP-HPLC (5-95% IPA in 0.1% TFA over 30 min, then 95% 
IPA for 20 min). Typically, within 24 hrs the mono addition product was isolated by 
column chromatography. 
Fmoc-Phe(4-NH2)-0Me (2.1). Fmoc-Phe(4-NH2)-0H (201.45 mg, 0.5 mmol) 
was added to a 250 mL of MeOH in a 500 mL Schlenk flask to form a slurry. 
Trimethylsilyl chloride (TMS-Cl, 126 J.!L, 1.0 mmol) was added slowly by syringe. All 
components became soluble upon the addition of TMS-Cl. The reaction was stirred under 
an inert atmosphere for 20 h then concentrated under vacuum. Yield: 198.8 mg, 95%. 1H 
NMR (400 MHz, MeOD): () 7.83 [2H, d, J(H-H) = 7.74 Hz, C-H, Phe], 7.63 [2H, d, J(H-
H) = 8.15 Hz, C-H, Phe], 7.42 (4H, m, C-H, Fmoc), 7.32 (4H, m, C-H, Fmoc), 4.48 (1H, 
m, aCH), 4.29 (2H, m, CHz, Fmoc), 4.18 (1H, m, CH, Fmoc), 3.75 (3H, s, CH3), 3.62 
(2H, m, aCHCH2). MALDVTOF, CHCA matrix, (M+1) requires mlz 417.17, found mlz 
417.34. 
Fmoc-Phe(4-NJ)-0Me (2.2). Compound 2.1 (41.7 mg, 0.1 mmols), ZnCh (33 uL 
of 0.03 M MeCN soln., 0.001 mmol), and Et3N (27.8 J.!L, 0.2 mmol) were dissolved in 
MeCN:MeOH (4:1, 5 mL) in a 25 mL round bottom flask and cooled in an ice bath. 
TfN33 (214 J.!L, 0.12 mmol) was added dropwise to the reaction mixture in MeCN. The 
reaction was removed from the ice bath and allowed to slowly warm up to room 
temperature. The reaction was stirred in the dark for 24 h. after which it was concentrated 
under vacuum. The residue was diluted with Et20 (50 mL) and filtered to remove 
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precipitates. The filtrate was dried under vacuum and the precipitate was washed with 
hexanes (3 x15 mL). Yield: 24.5 mg, 55%. 1H NMR (400 MHz, CDCb): 8 7.84 [2H, d, 
J(H-H) = 7.76 Hz, C-H, Phe], 7.62 [2H, d, J(H-H) = 8.13 Hz, C-H, Phe], 7.43 (2H, m, C-
H, Fmoc), 7.34 (6H, m, C-H, Fmoc), 6.12 [d, J(H-H) = 7.62 Hz, NH], 4.44 (1H, m, 
aCH), 4.29 (1H, m, CH2, Fmoc), 4.19 (2H, m, CH, Fmoc), 3.67 (3H, s, CH3), 3.19 [1H, 
dd, J(H-H) = 5.07 Hz, J(H-H) = 7.36 Hz, aCHCH2], 3.00 [1H, dd, J(H-H) = 6.85 Hz, 
J(H-H) = 9.39 Hz, aCHCH2].MALDIITOF, CHCA matrix, (M+1) requires mlz 443.48 
found mlz 443.62. 
Fmoc-Phe(4-N3)-0H (2.3). ISA·HCl (1.25 g, 6 mmol), Fmoc-Phe(4-NH2)-0H 
(2.01 g, 5 mmol), and ZnCh (27.3 mg, 0.2 mmol) were dissolved in MeOH:MeCN (3:2, 
300 mL) in a 500 mL Schlenk flask. Next triethylamine (1.39 mL, 10 mmol) was added. 
The reaction was stirred in the dark at room temperature for 12 hrs and monitored by thin 
film IR and TLC. Upon completion, the reaction was concentrated, diluted with 
diethylether (250 mL and washed with AcOH (10%, 3 x 150) and brine (1 x 200), dried 
over MgS04, filtered and concentrated under vacuum. At the gram scale, flash 
chromatography was used to yield the pure product. [10 -25 %ethyl acetate (with 1% 
AcOH) in hexanes]. Yield: 1.71 g, 80%. 1H NMR (400 MHz, CDCb): 8 7.78-7.32 (8H, 
m, C-H, Fmoc), 7.09 [2H, d, J(H-H) = 8.1 Hz, C-H, Phe], 6.93 [2H, d, J(H-H) = 8.55 Hz, 
C-H, Phe], 5.24 [1H, d, J(H-H) = 8.64 Hz, NH], 4.64 [1H, dd, J(H-H)= 4.68 Hz, J(H-H) 
= 12Hz, aCH], 4.47 [1H, dd, J(H-H) = 7.03 Hz, J(H-H) = 11.0 Hz, CH2, Fmoc], 4.37, 
[1H, dd, J(H-H) = 6.85 Hz, J(H-H) = 10.89 Hz, CH2, Fmoc], 4.19 [1H, t, J(H-H) = 6.81 
Hz, CH, Fmoc], 3.18 [1H, dd, J(H-H) = 5.39 Hz, J(H-H) = 14.24 Hz, aCHCH2], 3.06 
[?H, dd, J(H-H) = 6.07 Hz, J(H-H) = 14.29 Hz, aCHCH2]. IR VNJ = 2113 cm-1• 
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Boc-Phe(4-N3)-0H (2.4). ISA·HCl (1.25 g, 6 mmol), Boc-Phe(4-NH2)-0H (1.40 
g, 5 mmol), and ZnCh (27.3 mg, 0.2 mmol) were dissolved in MeOH:MeCN (3:2, 300 
mL) in a 500 mL Schlenk flask. Then triethylamine (1.39 mL, 10 mmol) was added. The 
reaction was stirred in the dark at room temperature for 12 hrs and monitored by thin film 
IR and TLC. Upon completion, the reaction was concentrated, diluted with Et02 (200 
mL) and washed with AcOH (10%, 3 x 200 mL) and brine (1 x 200 mL), dried with 
MgS04, filtered and concentrated under vacuum. At the gram scale, flash 
chromatography was used to yield the pure product. Yield: 1.3 g, 85%. 1H NMR (400 
MHz, CDC~]): 8 7.07 [2H, d, J(H-H) = 8.97 Hz, C-H], 6.97 [2H, d, J(H-H) = 8.63 Hz, 
C-H], 4.93 [1H, d, J(H-H) = 8.63 Hz, NH], 4.58 [1H, dd, J(H-H) = 6.64 Hz, J(H-H) = 
14.92 Hz, aCH], 3.18 [1H, dd, J(H-H) =5.12 Hz, J(H-H) = 13.92 Hz, CH2], 3.05 [1H, 
dd, J(H-H) =6.41 Hz, J(H-H) = 13.64 Hz, CH2], 1.42 [9H, s, C(CH3)3]. IR VN3 = 2115 
cm-1• 
Fmoc-Phe(4-N-aza/aziridino-C60)-0Me (2.5 alb). In a 250 mL Schlenk flask 
with a stir bar, C6o (39.6 g, 0.055 mmol) was vacuum dried for 45 min., then 100 mL of 
dry toluene was added by cannula and the mixture was heated to refluxing temperatures. 
Next 2.1 (24.5 mg, 0.055 mmol) dissolved in MeCN (50 mL) and added to the reaction 
by syringe. The reaction temperature was maintained around 100 °C for 48 h. This was a 
proof of concept experiment and therefore the compound was not characterized by NMR. 
MALDIITOF, DCTB matrix, (M-) requires mlz 1134.03, found mlz 1134.51. 
Fmoc-Phe(4-aza/aziridino-C6o)-OH (2.6 alb). In a 500 mL Schlenk flask, C60 
(1.68 g, 2.3 mmol) and 2.1 (1.0 g, 2.3 mmol) were vacuum dried for 45 min., then 350 
mL of dry ODCB was added by cannula. The reaction temperature was maintained 
around 165 °C for 4 hours or until the disappearance of starting materials by TLC. Due to 
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loss of product from precipitation, no work-up was performed. The product was purified 
by filtering through a large Si02 plug followed by stepped-gradient elution with toluene, 
followed by 5% EtOAc in toluene, followed by 5: 0.5:94.5 EtOAc: AcOH:toluene to 
elute the open isomer and 5:1.5:93.5 EtOAc: AcOH:toluene to elute the closed isomer. 
Yield: 825 mg, 32 %. 1H NMR (400 MHz, CDCh): 8 7.78-7.32 (8H, m, C-H, Fmoc), 
7.10 [2H, d, J(H-H) = 7.99 Hz, C-H (Phe)], 6.93 [2H, d, J(H-H) = 7.81 Hz, C-H (Phe)], 
5.19 [1H, d, J(H-H) = 7.06, NH], 4.66 (1H, m, aCH), 4.47 (1H, m, CH2 , Fmoc), 4.39, 
(lH, m, CH2, Fmoc), 4.20 [1H, t, J(H-H) = 6.75, CH, Fmoc], 3.19 [1H, dd, J(H-H) = 
4.93 Hz, J(H-H) = 13.88 Hz, aCH-CH2-C], 3.06 [1H, dd, J(H-H) = 4.79 Hz, J(H-H) = 
13.97 Hz, aCH-CH2-C]; MALDIITOF, DCTB matrix, (M") requires mlz 1120.14, found 
m/z 1120.23. 
Boc-Phe(aza/ziridino-C6o)-OH (2.7 alb). In a 500 mL Schlenk flask, C6o (1 g, 
1.38 mmol) and 2.2 (425.39 mg, 1.38 mmol) were vacuum dried for 45 min., then 350 
mL of dry ODCB was added by cannula. The reaction temperature was maintained 
around 80 °C and monitored by RP HPLC for the formation of the multiple addition 
products (usually within 24 hours). Due to loss of product from precipitation, no work-up 
was performed. The product was purified by filtering through a large Si02 plug followed 
by stepped-gradient elution with toluene followed by 5:95 EtOAc:toluene, followed by 
2.5:1:96.5 EtOAc:AcOH:toluene to elute the product. The pure isomers may be obtained 
by increasing the length of the column. Yield: 371.8 mg, 27 %. 1H NMR (400 MHz, 
CDCh): o 7.53 [2H, d, J(H-H) = 8.35 Hz, C-H], 7.24 [2H, d, J(H-H) = 8.97 Hz, C-H], 
5.02 [1H, d, J(H-H) = 7.47 Hz, NH], 4.62 (lH, m, aCH), 3.22 [1H, dd, J(H-H) =5.71 
Hz, J(H-H) = 12.74 Hz, CH2], 3.15 [1H, dd, J(H-H) = 7.91 Hz, J(H-H) = 13.67 Hz, 
CH2], 1.42 [9H, s, C(CH3)3] MALDIITOF, DCTB matrix, (M") requires mlz 998.13, 
found mlz, 998.16. 
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Boc-Lys(N3)-0Me (2.9). Dissolved Boc-Lys-OMe·AcOH (80.09 mg, 0.25 
mmols), ZnCh (333 uL of 0.03 M soln., 0.01 mmol), and Et3N (69.5 J.lL , 0.5 mmol) in 
MeCN:MeOH (4:1, 50 mL) in a 100 mL round bottom flask and cooled in an ice bath. 
TtN3 * (930 J.lL, 5.56 mmol) in MeCN was added dropwise to the reaction mixture. The 
reaction was removed from the ice bath and allowed to slowly warm up to room 
temperature. The reaction was stirred in the dark for 24 h. after which it was concentrated 
under vacuum. The residue was diluted with EtOAc (50 mL) and filtered to remove 
precipitates. The filtrate was washed with HNaC03 (2x 50 mL) and brine (1 x 50 mL), 
dried over MgS04, and concentrated under vacuum. Yield: 56.5 mg, 65%. 1H NMR (400 
MHz, CDCh) 8 5.13 [1H, d, J(H-H) = 7.18, NH], 3.75 (3H, s, CH3), 3.28 [2H, t, J(H-H) 
= 6.93, CHz-N], 3.22 (lH, m, aCH), 1.81 (2H, m, aCH-CH2), 1.64 (4H, m, CH2-CH2), 
1.45 [9H, s, C(CH3)3]. IR vN3 = 2099 cm·1• 
Boc-Lys(N3)-0H (2.8). Dissolved Boc-Lys-OH (123.15 mg, 0.5 mmols), ZnCh 
(666.5 uL of 0.03 M soln., 0.02 mmol), and Et3N (104.3 J.lL, 0.75 mmol) in 
MeCN:MeOH (4:1, 50 mL) in a 100 mL round bottom flask and cooled in an ice bath. 
TfN3* (3.4 mL, 0.75 mmol) in MeCN was added dropwise to the reaction mixture. The 
reaction was removed from the ice bath and allowed to slowly warm up to room 
temperature. The reaction was stirred in the dark for 24 h. after which it was concentrated 
under vacuum and then diluted with CHCh and filtered. The filtrate was washed with 
HNaC03 (2x 50 mL) and brine (1 x 50 mL), dried over MgS04, and concentrated under 
vacuum to a yellow oil. Flash chromatography is necessary at the gram scale. Yield: 80.1 
mg, 58%. 1H NMR (400 MHz,CDCb): o 5.15 [1H, d, J(H-H) = 8.59, NHJ, 4.33 [1H, dd, J(H-H) 
= 6.72, J(H-H) = 12.8 Hz, a.CHJ, 3.29 [2H, t, J(H-H) = 7.43 Hz, CH2-N3], 1.90 [IH, m, a.CH-
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CH2], 1.72 [1H, m, aCH-CH2], 1.64 [2H, m, CH2], 1.51 [2H, m, CH2], 1.45 [9H, s, C(CH3)3]; IR 
vN3 = 2127 cm-1. 
Boc-Lys(N3)-0tBu (2.10) Dissolved compound 2.9 (27.3 mg, 0.1 mmols), 
EDC·HCl (1-Ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride, 14.8 mg, 
0.077 mmol), tert-butanol (7.8 f..lL, 0.083 mmol), and a catalytic amount of 
dimethylaminopyridine (DMAP) in CH2Ch (50 mL) in a 100 mL round bottom flask. 
The reaction was stirred in the dark until no starting material remained, ~24 h., after 
which it was diluted with CH2Ch and washed with HCl (10%, 3 x 50 mL) and brine (1 x 
100 mL), dried over MgS04, and concentrated under vacuum to a yellow oil. Yield: 27.9 
mg, 85%. 1H NMR (400 MHz, CDCb) () 5.14 [1H, d, J(H-H) = 8.84, NH], 4.84 (1H, m, 
aCH), 3.60 (lH, m, CH2-N), 3.51 (1H, m, CH2-N), 1.91 (2H, m, aCH-CH2), 1.78 (2H, 
m, aCH-CH2), 1.68 (2H, m, CH2-CH2), 1.62 (2H, m, CH2-CH2), 1.46 (9H, s, CCH3), 
1.42 [9H, s, C(CH3)3]. IR VNJ = 2099 cm-1. 
Boc-Lys(4-aza/aziridino-C6o)-0Me (2.11 alb). In a 500 mL Schlenk flask, C6o 
(180 mg, 0.25 mmol) was vacuum dried for 45 min. then 200 mL of dry toluene was 
added by cannula. The reaction was brought to refluxing temperatures for solubility of 
C6o then allowed to cool down to 60 °C. Compound 2.8 (86.6 mg, 0.25 mmol) was 
dissolved in THF (3 mL) and added by syringe to the reaction. The temperature was 
maintained at 60 °C and monitored by RP HPLC for the formation of the multiple 
addition products(usually within 72 hours). This was a proof of concept reaction 
performed to determine if protection of the carboxy terminus was necessary and the 
reaction products were only characterized by MALDI MS. The reaction mixture was 
washed with NaHC03 (2x 200 mL) and brine (1 x 200 mL) then dried over MgS04 and 
concentrated under vacuum. The residue was purified by flash chromatography eluting 
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with hexanes:toluene (4:1) to remove excess C6o, followed by a gradient elution with 
EtOAc in toluene (2- 20%) to co-elute the isomers. Yield: 31 mg, 13%. 1H NMR (400 
MHz, CDCh) o 5.11 [lH, d, J(H-H) = 7.84, NH], 4.42 (lH, m, a.CH), 3.78 (3H, s, CH3), 
3.77 (2H, m, CH2-N), 2.03 (2H, m, a.CH-CH2), 1.80 (4H, m , CH2-CH2), 1.47 [9H, s, 
C(CH3) 3]. MALDIITOF, DCTB matrix, (M") requires m!z 978.12, found mlz 978.44. 
Boc-Lys(4-aza/aziridino-C60)-0tBu (2.12 alb). In a 500 mL Schlenk: flask, C6o 
(180 mg, 0.25 mmol) was vacuum dried for 45 min. then 200 mL of dry toluene was 
added by cannula. The reaction was brought to refluxing temperatures for solubility of 
C6o· Compound 2.10 (82 mg, 0.25 mmol) was dissolved in THF (3 mL) and added by 
syringe to the reaction. The temperature was maintained around 1 00 °C and monitored by 
RP HPLC for the formation of the multiple addition products (usually within 72 hours). 
The reaction mixture was washed with NaHC03 (2 x 200 mL) and brine (1 x 200 mL) 
then dried over MgS04 and concentrated under vacuum. The residue was purified by 
flash chromatography eluting with hexanes:toluene (4:1) to remove excess C60, followed 
by a gradient elution with EtOAc in toluene (2- 3%) to co-elute the isomers. Yield: 28.1 
mg, 11 %. MALDI/TOF, DCTB matrix, (M") requires m/z 1020.43, found mlz 1020.62. 
Boc-Lys(4-aza/aziridino-C6o)-OH (2.13 alb). In a 500 mL Schlenk: flask, C60 
(1.0 g, 1.39 mmol) and 2.8 (272.15 mg, 1.39 mmol) were vacuum dried for 45 min. then 
200 mL of dry ODCB was added by cannula. The reaction temperature was maintained at 
60 °C and monitored by RP HPLC for the formation of the multiple addition 
products(usually within 72 hours). Due to loss of product from precipitation, no work-up 
was performed. The product was purified by filtering through a large Si02 plug, followed 
by stepped gradient elution with toluene to remove unreacted C60, then CH2Ch. Next 
60:39.5:0.5 CH2Ch:toluene:AcOH was used to elute the aza-derivative, followed by 
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79:20:1 CH2Ch:toluene:AcOH to elute the aziridino product. Yield: 187.5 mg, 14%. 
MALDI/TOF, DCTB matrix, (M") requires mlz 964.14, found m/z 964.06. 1H NMR (500 
MHz, CDCh) (a) 8 5.09 [1H, d, J(H-H) = 7.18, NH], 4.43 (1H, m, aCH), 3.81 [2H, t, 
J(H-H) = 7.20 Hz, CH2-N], 2.06 (1H, m, CH2), 1.89 (1H, m, CH2), 1.82 (2H, m, CH2), 
1.57 (2H, m, CH2), 1.48 [9H, s, C(CH3)3]; 1H NMR (b): 8 5.09 [1H, d, J(H-H) = 7.76, 
NH], 4.42 (1H, m, aCH), 3.69 [2H, t, J(H-H) = 6.90 Hz, CH2-N], 2.05 (2H, m, CH2), 
1.91 (2H, m, CH2), 1.82 (2H, m , CH2), 1.62 (2H, m, CH2), 1.48 [9H, s, C(CH3)3]. 
This compound has a tendency to stick on a Si02 column. The yield can be 
improved by precipitating the product with hexanes, then washing the precipitate (3 x 50 
mL, 4:1 hexanes:toluene) to remove C60. The pellet was then dissolved in CHCh and 
filtered through a Si02 plug. Elute with toluene then DCM. Use 79:20:1 
DCM:toluene:AcOH to elute both isomers. 
Phe(4-aza-C6o)-OH (2.14). The Boc protecting group of compound 2.6a (25 mg, 
0.02 mmols) was removed by 25% TFA in dry dichloromethane. The residue was stirred 
with an excess of the reagent for 6 - 8 hrs in a glass vial. Cold Et20 was added to the vial 
and the product was allowed to precipitate in the freezer overnight. The precipitate was 
washed with Et20 (3 x 15 mL) and centrifuged. Yield: 16.2 mg, 90%. 1H NMR (500 
MHz, DMSO-d6): o 8.28 2H, bs, NH2, 7.67 [2H, d, J(H-H) = 8.54 Hz, C-H], 7.67 [2H, d, 
J(H-H) = 8.66 Hz, C-H], 4.21 1H, m, aCH, 3.15 [1H, dd, J(H-H) = 5.82 Hz, J(H-H) = 
13.98 Hz, CH2], 3.09 [1H, dd, J(H-H) = 7.05 Hz, J(H-H) = 13.74 Hz CH2]. 
MALDI/TOF, (M-) requires m/z 898.07, found m/z 898.02. 
Phe(4-aza-C6o)-OH (2.14). The FMOC protecting group of2.5a, was removed by 
the addition of 0.5 mL of 20% piperidine in DMF to a solution of 2.5a (77 mg, 0.067 
mmol) in DMF (0.5 mL) and briefly sonicated then allowed to stir. After 10 minutes, the 
solution was diluted with 5 M HCl and centrifuged at 4400 RPMs for 5 minutes. The 
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water soluble fullerene amino acid supernatant was then lyophilized to dryness. Yield: 
36.5 mg, 60%. MALDI MS (M+1, CHCA) requires mlz 898.07, found 898.28. 
Fmoc-Phe(4-aza-C6o)-Giy-OtBu (2.14). 2.5 a was coupled to tert-butyl ester of 
glycine to determine its reactivity. The coupling was performed in anhydrous DMF with 
1 eqiv. of HBTU and 2 eqiv. of triethylamine under inert conditions. After 2 hours, 
MALDIITOF (CHCA matrix) showed only starting materials and product formation at 
mlz 1234.11. Calculated (M + 1): mlz 1234.23. 
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Chapter3 
Fullerene-Based Inhibitors ofHIV-1 Protease 
Introduction 
As discussed in the previous chapters, fullero-peptides utilizing an unnatural C60 
amino acid in the sequence are not a recent construct. Prato was the first to report the 
synthesis of a fullerene peptide, recognizing the novel properties a fullerene might impart 
to biological molecules. 1 Since that time our laboratory has produced several fullerene 
peptides to investigate their cellular penetrating properties and their inhibition of 
neuroblastoma, a cancer affecting children.2 Others have investigated the cytotoxicity, 
DNA cleavage, and enzyme inhibition by fullerene amino acids, peptides and other C60 
derivatives. 3 One of the enzymes studied in regards to inhibition by fullerene is human 
immunodeficiency virus-1 protease (HIV -1 PR). 
When a person is infected with HIV the virus encodes for several enzymes, 
including reverse transcriptase (RT), integrase, and protease. The first two enzymes are 
responsible for transcribing and integrating the virus's genetic material into that of the 
host's, thereby hijacking the host's cells to produce viral proteins. HIV-1 PR is one ofthe 
viral proteins produced. It is an aspartic protease responsible for catalyzing the hydrolysis 
of precursor polyproteins associated with HIV infection. 4 Without the function of either 
RT or PR, the virus fails to mature and does not become infectious. Both, RT and PR 
have become popular targets for HIV inhibition. 5 
Aspartic proteases (Asp PRs) are a broad class of enzymes involved in many body 
processes, such as digestion and pregnancy. Aspartic pro teases are characterized by 
optimal activity in the low pH range (1 - 5), two catalytic aspartic acid residues present 
in the dimerized protease, and inhibition by pepstatin A, a peptide inhibitor of all Asp 
PRs (Figure 3.1).4 Asp PRs have been isolated from most forms of life, including plants, 
vertebrates, fungi, and retroviruses, where they are responsible for cleaving immature 
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polypeptide substrates. 6 HIV -1 PR was one of the first retroviral proteases to be studied 
by X-ray diffraction7 and pepsin, a digestive enzyme and aspartic protease, was the first 
protein ever to be analyzed by X-ray diffraction. 8 
OH 
Figure 3.1. The structure ofpepstatin A, a peptide inhibitor of all aspartic proteases is 
shown. 
The structures of Asp PRs are somewhat variable with about 5% of the structure 
conserved between all strains. 6 Functional retroviral aspartic proteases form a 
homodimer, with two identical monomers each contributing a highly conserved region 
near the catalytic aspartic acids (Figure 3.2). The highly conserved region consists of a 
triad of residues, Asp-Thr-Gly, and other hydrophobic residues, such as alanine and 
phenylalanine.9 In their monomeric form retroviral PRs are catalytically inactive. In the 
highly conserved region, the aspartyl residues are in close proximity to each other and 
coordinate to a water molecule; it is believed that this coordination is a major source of 
the stability of the dimer as a whole. 10 Depending on the presence and structure of the 
inhibitor, only one of the aspartyl residues is protonated at a time, due less to the pH of 
the environment and more to their proximity to each other.4 In fact, the two aspartyl 
residues have different pKa's of 3.1 and 5.2 for the deprotonated and the protonated 
residue respectively. 11 
In addition to the asapartyl residues, the dimerized enzyme contains a binding 
pocket made up of various hydrophobic amino acids. This forms the active site, or of 
HIV -1 PR and is the region where mutations often occur in response to specific 
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interactions with inhibitors.4 The active site is covered over by one or two binding loops 
or flaps, depending on whether they are cellular or retroviral PRs respectively, which take 
part in binding to substrates and inhibitors. For nomenclature purposes the binding pocket 
is divided into subsites composed almost entirely of hydrophobic residues. Figure 3.3 
shows the standard nomenclature used to designate both binding pocket subsites and the 
corresponding interaction points on the peptide substrate in addition to the location of the 
scissile, or cleaved, bond.4 
Flaps 
.( 
Figure 3.2. The dimerized structure of HIV -1 PR illustrating the location of the catalytic 
aspartyl residues, the flaps, and the binding pocket where the substrate or inhibitors fit is 
12 
shown above. 
In a general acid-base mechanism, the nucleophilic aspartyl residue initiates 
peptide hydrolysis by deprotonating a coordinated water molecule, or thiol in some cases, 
thereby generating a nucleophile capable of cleaving the amide bond. Although the exact 
mechanism is not known, Figure 3.4 shows the generally accepted mechanism of 
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catalysis of retroviral Asp PRs whether that be through a concerted reaction or through a 
series of separate steps. 13 
s, 
Proa1' Va182' 83 
lle84' Leu23' 
lleso 
s2 s,· S3' 
,-.... ,.-..... ~ 
0 P2 0 P,' 0 P3' 'Y~~~Y1~JY~0~~i 
p3 0 p1 scilllle 0 P2' 
'-"' '-.-./ bond '--./ 
S3 s, ~· 
Arg6 Asp29' n~· 
Figure 3.3. This is the standard nomenclature used to reference the peptide substrate 
residues (P1-Pn) and their corresponding binding sites on HIV-1 PR (Sl-Sn), including the 
specific amino acids present, in relation to the scissile peptide bond. The prime notation 
(')refers to one monomer of the dimerized protease. 10 
The determination of the structure and potential mechanism of Asp PRs was a 
result of the initial sequencing and crystal structure of pepsin, the digestive enzyme, and 
through co-crystalization of various Asp PRs with the inhibitor pepstatin.9-10 Those 
events allowed researchers to intelligently design several classes of new inhibitors based 
on a remarkably accurate model of the binding pocket and its relevant interactions with 
inhibitors. Of primary importance were: (1) displacement of the nucleophilic water 
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molecule, (2) hydrogen bonding between the enzyme and the peptide backbone of 
pepstain, (3) VDW interactions between the sidechains of pepstatin and enzyme residues, 
usually hydrophobic, and (4) a conformational change in the flap of the enzyme allowing 
more favorable hydrogen bonding opportunities with pepstatin. 10 Through the combined 
efforts of many researchers, several classes of aspartic protease inhibitors (PRis) 
emerged. 
- -
Figure 3.4. The proposed acid-base mechanism of proteolytic cleavage, including the 
tetrahedral intermediate, by this type of aspartic protease. 14a The other type of protease is 
a metallo-protease in which a zinc ion is coordinated to the substrate as a Lewis acid and 
generating an activated carbonyl. 10 
Since the substrate and the first known inhibitor of HIV -1 PR, pepstatin A, are 
both peptides, most early inhibitors were either peptides or were designed as substrate 
mimics. One observation made from these early studies was that HIV -1 PR was able to 
recognize and cleave the Tyr-Pro or Phe-Pro (Figure 3.5) dipeptide sequences of viral 
polyproteins, unlike cellular proteases, and it was correctly thought that this condition 
may impart some level of specificity for HIV -1 PR. 14 The knowledge gained from these 
early inhibitors along with the knowledge that enzymes lower the activation energy of a 
reaction through specificity for either or both the substrate and the transition state 
allowed the development of another class of PRis. 
HO Tyr-Pro Phe-Pro 
Figure 3.5. Dipeptide subunit recognized and cleaved by HIV -1 PR but not by cellular 
PRs. The red line represents the scissle bond that is cleaved during proteolysis. 
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Based on the previous studies, a new series of peptidomimetic inhibitors were 
designed to imitate the tetrahedral transition state of the enzyme catalyzed reaction. 
Several structures were considered to emulate the proteolytic transition state of the Tyr-
Pro or Phe-Pro dipeptide structure; the most successful of which was a nonhydrolyzable 
hydroxyethylamine subunit.4 In fact, nine out of ten of the currently available, FDA 
approved, inhibitors use a nonhydrolyzable hydroxyethylene or hydroxyethylamine 
subunit at the core (Table 3.1), one as a prodrug. In addition to the specificity for the 
dipeptide sequence, it was also discovered that an R stereoconfiguration at the central 
carbon bearing the hydroxyl group was preferred for short protease inhibitors (PRis). 15 
The crystal structures of such transition state isosteres with HIV -1 PR confirm that they 
make favorable interactions with the two catalytic Asp residues where the coordinated 
water molecule usually resides. 15 There are currently ten marketed, FDA approved, 
protease inhibitors for HIV -1 PR; they are depicted in Table 3.1 in the order of their FDA 
approval, along with the stereoconfiguration at the hydroxyl bearing carbon and their 
inhibition constant, Ki. 
The potency of an enzyme inhibitor is evaluated by monitoring the kinetics of the 
enzymatic reaction. This is accomplished by quantifying substrate depletion or product 
formation through chromogenic, radiometric, or HPLC based assays. 15 The values are 
usually given as EC5o, the dose required to effect a 50% decrease in the initial reaction 
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velocity, or as Ki. the inhibition constant; both are reported in units of molarity. The 
inhibition constant is actually the dissociation constant of the enzyme/inhibitor complex 
and is considered to be a more accurate reflection of the pharmacokinetics of the inhibitor 
with the enzyme. In many cases the EC50 is roughly equivalent to the apparent Ki. 
However, in the case of tight binding inhibitors such as ours, the ECso depends on the 
enzyme concentration and other conditions of the assay such as temperature and buffers. 
An inhibitor is considered to be tight binding when the inhibitor concentration used in the 
assay is near the total enzyme active site concentration, [I] :::: [Et]. Due to their 
dependence on assay conditions, EC5o values are not always comparable to each other 
whereas the inhibition constant, Ki. is a measure of the rate of dissociation of the complex 
and is therefore comparable to any other Ki measurement. In any case, the ECso 
measurement is a less rigorous evaluation and is commonly used in high through put 
screening of inhibitors to determine lead compounds and can be converted to the Ki if 
other kinetic parameters of the substrate are known. 20 
The effectiveness ofPR inhibitors has been diminished by the virus's high rate of 
mutation forcing patients to take "cocktails" of drugs to combat the constantly changing 
virus. There have been at least 1929 drug induced mutations isolated from "resistant" 
patients. Most mutations occur in the binding pocket in response to the Pt!P3 sites on 
inhibitors.4 One of the FDA inhibitors, tipranavir, is a non-peptidic PRI and is only 
administered in conjuction with ritonavir as a combination therapy. It is an extremely 
potent inhibitor that does not use the hydroxyethylamine subunit and has been effective 
in patients with drug resistance due to mutations. Tipranavir is only administered to 
patients that have shown resistance to multiple protease inhibitors as it can cause life 
threatening side effects such as severe liver damage. 17 To date, tipranavir combination 
therapy is the most successful, albeit hazardous, strategy for combating the ever changing 
virus. The need for structurally novel inhibitors of HIV -1 PR is evident. 
Table 3.1. FDA approved protease inhibitors. 4' 16 
Generic 
Name 
saquinavir 
mesylate 
ritonavir 
in dina vir 
nelfinavir 
mesylate 
amprenavir 
lopinavir and 
ritonavir 
atazanavir 
sulfate 
Ki (nM) Stereoconfiguration 
ofC-OH 
0.12 R 
0.01 s 
0.56 s 
2 R 
0.6 R 
0.003 s 
0.75 s 
fosamprenavir 
calcium 80 (ICso) R 
tipranavir for 
resistance 
darunavir 
0.01 
0.0045 R 
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Structure 
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In an effort to find new and potent inhibitors of HIV -1 PR, many molecules have 
been considered. The fit of C60 with the binding pocket of HIV -1 PR was first proposed 
by Friedman in 1993, and in fact, was initially a joke between frustrated graduate 
students. The joke evolved into an epiphany as Friedman looked more closely at the ~ 1 
nm diameter, hydrophobic binding pocket in relation to the buckyball. He realized that 
C60 would actually make quite a nice fit, both through steric and electrostatic 
interactions. 17 Since Friedman's initial work many others have attempted to improve the 
affinity of fullerene derivatives for the active site of HIV -1 PR. 18 Despite many attempts 
by several researchers to make a potent, water soluble, fullerene PRJ, the most potent of 
the fullerene inhibitors (1 03 nM) was designed by Friedman and co-workers by modeling 
hydrophobic desolvation upon complex formation with PR. 19 Figure 3.6 shows the most 
potent fullerene inhibitors of HIV -1 PR, their inhibition constant, Ki. when available, 
and/or their ECso. 
OH 
EC502ZOnM 
K1103nM 
•· R 
(a) R = ((CH2)20k(CH2!2NH3 •·c1, X = Cl 
(b) R=Me,X=I 
(a) EC50 400 nM 
(b) EC50 210 nM 
Figure 3.6. The structures of selected fullerene based PRis are shown above with their Ki 
orECso. 
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New enzyme inhibitors' are screened by evaluating the kinetics of the enzymatic 
reaction. The kinetic behavior of many simple enzymes is approximated by Michaelis-
Menten (M-M) kinetics.20 M-M kinetics assumes that there is no intermediate of the 
reaction, no cooperativity with other substrates, enzymes or cofactors, and no product 
inhibition during the course ofthe reaction. M-M kinetics requires that the rate of product 
formation is linear with time and proportional to both substrate and enzyme 
concentration. The corresponding reaction progress curve to determine initial reaction 
velocity, vo, is a rectangular hyperbola following Eq. 3.1, where Vmax is the maximum 
rate or velocity, [S] is the substrate concentration and Km is the M-M constant. The Km is 
defined as the substrate concentration at which the reaction velocity is at half its 
maximum value, YlV max· It is a kinetic constant and is meant to provide a consistent 
method of evaluating substrate saturation of an enzyme active site. The value of Km 
depends on environmental factors such as pH, temperature, and ionic strength. In an 
inhibition assay the substrate concentration should be near the Km to prevent competition 
with the inhibitor. 21 
vo= 
Vmax[S] 
Km+ [S] 
(3.1) 
The Km of a substrate is determined by evaluating the initial velocity, vo, of 
substrate hydrolysis at various substrate concentrations in the absence of an inhibitor. 
During the initial phase of the reaction, when substrate depletion should be < 10 - 15% of 
the starting value, a steady state is reached where [S], [ES], the concentration of the 
enzyme substrate complex, and the reaction rate are constant and the reaction velocities 
are well described by a plot of product formation versus time. In a typical kinetic assay, 
enzyme concentrations are in the nM range while substrate concentrations are in the 
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micro to milli molar range. This condition ensures that the substrate concentration [S] is 
roughly constant throughout the "initial phase" of the reaction. The kinetic parameters Km 
and V max can be determined by fitting the data from the reaction progress curve through 
non-linear regression using the M-M equation (Eq. 3.1)?0 
In addition to the Km and V max, the total enzyme active site concentration, [Et], 
must also be determined to evaluate the inhibition of an enzyme. The concentration of 
HIV -1 PR added to an assay is not the same as the total active site concentration. An 
enzyme is in constant flux between dimerized and monomeric forms. Even then the 
dimerized protein may not be in an active conformation; therefore, the [Et] must be 
determined experimentally. The empirical determination of [Et] is accomplished by 
titration with a tight binding inhibitor. As discussed previously, a tight binding inhibitor 
is effective at low concentrations somewhere near the total enzyme concentration.Z1 In 
plot of fractional velocity (v/vo) versus [I] the point where the linear portion of the curve 
intersects the x-axis is the total enzyme active site concentration, [Et]. 
The kinetic behavior ofHIV-1 PR with our inhibitors was evaluated by a cell-free 
fluorescence resonance energy transfer (FRET) based assay using a FRET peptide 
substrate. FRET based assays have become a popular method for high throughput 
screening of potential pharmacophores.Z2 FRET is a distance dependant interaction and a 
FRET peptide consists of three main parts: a donor fluorophore (D), a quencher or 
acceptor molecule (A), and a linker between the two. When the donor is excited, its 
energy is transferred to the acceptor without the emission of a photon. Usually the 
emission wavelength of the D moiety overlaps with the absorption wavelength of the 
acceptor. When the linker/peptide is cleaved the donor and acceptor are separated and the 
energy is no longer transferred resulting in a quantifiable fluorescence signal.23 The 
FRET peptide used in our assay is derived from the native cleavage site on the 
polyprotein substrate ofHIV-1 PR.23 
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In our investigation of fullerene inhibitors of HIV -1 PR we wanted to answer 
several questions: 1) will a fullerene amino acid be a good base for the design of 
fullerene-based PRis; 2) will subtle changes to the C60 amino acid core affect the 
achieved inhibition; 3) can we improve the inhibition ofthe fullerene amino acid through 
the incorporation of a designer peptide tail; and 4) what properties of HIV -1 PR can we 
exploit to improve the observed inhibition? Given that the synthesis and purification of 
fullerene compounds can be time-consuming and expensive, the use of a molecular 
docking (MD) simulation aided us in the discovery of lead compounds and in the design 
of new inhibitors.24 In collaboration with a group of theoretical chemists with a molecular 
docking (MD) simulation relating to C60 derivatives with HIV-1 PR 25 and a group of 
biologists, we set out to experimentally verify the predictive ability of their modeling 
program with our fullerene amino acids. With the knowledge gained from these 
experiments, the ultimate goal was to design more active, fullero-peptide inhibitors of 
HIV-1 PR. 
The rational for the design of our first peptide inhibitor was based on the structure 
of HIV -1 PR itself. Our intention was to exploit the structure of HIV -1 PR for our 
purposes with a chain of positively charged amino acids which should result in the 
formation of a salt bridge with the aspartyl residues. Our hypothesis was that a poly-Lys 
peptide tail would provide both the positive charges and enough flexibility for the 
electrostatic interaction to occur. In addition to the electrostatic interaction, the poly-Lys 
tail should also improve the aqueous solubility of the C6o amino acid. Even without the 
electrostatic interactions, at a minimum, the poly-Lys tail should provide many H-bond 
donors and acceptors. We used Lipinski's rule of five for drug candidates as a guide in 
our inhibitor design. 26 The rule of five states that a drug lead should have no more than 
five H-bond donors, ten H-bond acceptors, a molecular weight under 500 and an octanol-
water partition coefficient of 5 to be "druglike" and orally available. A tripeptide was 
determined to be the minimum length tail necessary to achieve our goals despite 
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disregarding most of Lipinski's guidelines. The structure of the tripeptide tail is shown in 
Figure 3.7. 
Figure 3.7. The structure of the poly-Lys peptide tail. 
Ultimately we wanted to design a transition state mimic with our peptide 
structure. In the design of our transitions state isosteres we used the knowledge that HIV-
1 PR can recognize a Phe-Pro dipeptide subunit. Utilizing our C6o amino acid as the Phe 
component, we designed a sequence including Pro-Hyp-Lys (Figure 3.8a). The proline 
residue provides the recognition element required for specificity to HIV -1 PR. The 
hydroxyproline residue provides the tetrahedral transition state analog with R 
stereoconfiguration at the hydroxyl bearing carbon. The final lysine residue was added 
both for aqueous solubility and to provide additional H-bonding opportunities with the 
binding pocket residues of HIV -1 PR. The goal for this inhibitor was that the Hyp residue 
will push the coordinated water molecule out of the binding pocket thereby eliminating 
the threat of hydrolysis of the substrate. 
Along the same vein, another peptide inhibitor utilizing the sequence Hyp-Hyp-
Lys was considered (Figure 3.8b). The same principles as discussed for the Pro-Hyp-Lys 
sequence apply. Our supposition was that the Phe-Hyp will also be recognized by HIV-1 
PR as it is very similar structurally to Phe-Pro. The addition of the second OH group 
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present on Hyp allows another opportunity for H-bonding and given that we do not know 
exactly where either hydroxyl group will actually reside the switch from Pro to Hyp is 
simply a way of determining if one of those positions will have more favorable 
interactions than the other. Figure 3.8 shows both transition state isosteres. 
Figure 3.8. The structures of the peptide tails of our transition state isosteres (a) Pro-
Hyp-Lys and (b) Hyp2-Lys. 
Results and Discussion 
The use of fullerene amino acids and peptides as inhibitors of HIV -1 PR was 
investigated through MD simulations and biological assays. The computational and 
biological methods utilized by our collaborators are reported elsewhere.25 Briefly, the MD 
simulations were performed using a crystal structure of haloperidol, a small molecule 
inhibitor of HIV -1 PR, in the binding pocket of HIV -1 PR (PDB code: 1 AID). All of the 
waters of crystallization remained throughout the simulation but are freely rotatable and 
replaceable by the ligand, i.e., the inhibitor. 
In our preliminary examination of fullerene amino acids as inhibitors of HIV -1 
PR we investigated a number of factors, including amino acid core and protecting groups, 
to determine if subtle changes in the C6o amino acid base would have an effect on the 
observed inhibition. Several of the compounds assayed are illustrated in Table 3.2. 
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Many of the compounds tested are not the subject of this thesis but are reported in 
Appendix A to illustrate the quality of the data obtained by this computational method. 
The synthesis of the compounds was reported elsewhere?7 Experimental binding 
affinities (Ki) are converted into binding energy for comparison to simulated values by 
the equation .10 =- RT ln Ki. 
Table 3.2. Selected inhibition and MD simulation data from collaborators. 
Structure and name 
Fmoc-Baa 
~ 
M s 
*01 •Q 
Baa 
Phe( 4-aza-C6o)-OH (2.13) 
Experimental Experimental Simulated 
binding affinity, binding energies binding energies 
(nM) 
36 
124 
119 
(kJ/mol) 
-42.75 
-39.67 
-39.77 
glide/IFD 
(kJ/mol) 
-46.69 
-38.28 
-40.00 
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A plot of the simulated binding energies versus the experimental binding energies 
showed moderately good agreement between the predicted value and the experimental 
value (R2 = 0.82, Figure 3.9). While the modeling program could not be considered to be 
predictive based on the agreement between experimental and simulated values, the data 
provided by the MD simulations is a good starting point in determining whether or not 
the compounds are worthwhile to synthesize. 
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Figure 3.9. The linear regression analysis illustrating the agreement between simulated 
binding energies and experimental binding energies (R2 = 0.82). 
Based on the results, we were able to come to some conclusions about our 
fullerene amino acid inhibitors. The most important observation during these preliminary 
experiments was that the presence of the Fmoc protecting group on Baa improved the 
inhibition dramatically as compared to the corresponding free amine Baa. Initially this 
was surprising but an inspection ofthe binding pose ofFmoc-Baa with HIV-1 PR showed 
that the large aromatic Fmoc group makes favorable interactions with the hydrophobic 
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binding pocket (Figute 3.10). Also determined from these experiments was the fact that 
the Diels-Alder fullerene amino acid, Baa, and the newly reported Phe( 4-aza!aziridino-
C6o)-OH, 2.13, had nearly equivalent binding affinities. Given that Baa and 2.13 showed 
similar inhibition, we speculated that the corresponding Fmoc derivatives (Fmoc-Baa and 
2.6) would follow the same trend. Therefore, we used Fmoc-Phe( 4-azalaziridino-C60)-0H 
(2.6) as the fullerene amino acid base for our peptide inhibitors due to its ease of 
preparation. 
Figure 3.10. Binding pose ofFmoc-Baa with HIV-1 PR. The red circle highlights the 
. 25 Fmoc protecting group. 
All C60 peptide inhibitors were made through solid phase peptide synthesis 
(SPPS). The peptide tail was purchased on the resin in its crude form. Compound 2.6 was 
coupled to the peptide in the dark through standard Fmoc procedures. Due to the acid 
sensitivity of 2.6, a solution of 20:2.5:77.5 TFA:triisopropylsilane (TIPS):CH2Ch was 
used to cleave the completed peptide sequence off the resin rather than the customary 
95:2.5:2.5 TFA:TIPS:H20. Figure 3.11 shows the final structure of the three peptide 
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inhibitors and their MD simulated Ki· Figure 3.12 shows the binding pose of compounds 
3.1 with HIV -1 PR as predicted by the MD simulation. 
3.1 
(0 .07 nM) 
(predicted binding affinity . nM) 
3.2 
(1 .7nM) 
Figure 3.11. The structures of the C60-peptides designed as inhibitors of HIV -1 PR are 
shown above. In parentheses is the binding affinity as predicted by MD simulations. 
Figure 3.12. Binding pose of compound 3.1 as predicted by MD simulations. The red 
circle highlights the interaction of the Fmoc protecting group with a Phe residue. 
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The acidic cleavage from the SPPS resin results in a small degree of C60 loss and 
some conversion of the aza linkage to a primary amine. These were the minor impurities 
present by ESI/ToF MS in the peptide inhibitors post cleavage. The purity of the peptides 
cleaved from the resin was determined by HPLC with detection at 220 for the peptide and 
330 nm for C6o· Figure 3.13 shows an HPLC chromatogram of 3.1 illustrating their purity 
after cleavage from the resin. Based on ESI MS, the low retention time impurities are the 
amino peptide minus C60 and uncoupled peptide. 
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Figure 3.13. Typical HPLC chromatograms of the C60 peptides, with detection at 220 nm 
for the peptide moieties and 330 nm for the C60 moiety, illustrating the purity of the 
peptides after cleavage from the resin. 
Due to the tendency of the C6o peptides to stick to any sort of column packing 
material, column purification was avoided when possible. Instead, peptide inhibitors were 
dissolved in DMSO at a concentration of -500 J.lM and filtered through a C, 8 coated Si02 
plug to remove any C60 present. The only impurity remaining was the amino peptide 
minus C60, which has absorbance at 220 nm (peptide bond) and 256 nm (Phe residue). 
Therefore, the concentration of the C60 peptide inhibitors used in the assays was 
determined by UV at 330 nm (£ 0.0383 J.1M-1cm-1) to eliminate any absorption from 
amino peptide minus C60 (absorbance 256 nm). 
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To determine the inhibition constant of our fullerene PRis we utilized a FRET 
based assay to evaluate the enzyme kinetics of HIV -1 PR at various concentrations of 
inhibitors. To evaluate the Km of our FRET substrate with HIV-1 PR we monitored the 
substrate hydrolysis at various substrate concentrations in the absence of inhibitors. The 
[Et] was determined by titration with a tight-binding inhibitor. The Km of our substrate 
was determined to be approximately 1 J.lM and the [Et] used in the assays was determined 
to be 37.5 nM (Experimental). In addition to the kinetic constant Km and the [Et], a series 
of control experiments were also performed (Table 3.3). 
Table 3.3. Control experiments performed before PRJ analysis. 
Control Description Determination 
positive no test compound uninhibited reaction velocity, v0 
inhibitor pepstatin A known inhibitor of HIV -1 PR 
vehicle DMSO inhibition due to vehicle 
test compound assay buffer, no enzyme autofluorescence of C6o PRis 
substrate assay buffer, no enzyme baseline 
C6o amino acid Fmoc-Phe( 4-NH2)-0H inhibition due to C6o 
C6o peptide Fmoc-Phe( 4-NH2)-Pro-Hyp-Lys inhibition due to C6o 
hydrophobic Stearic acid-Lys3 inhibition due to hydrophobicity 
The inhibition constants of several amino acid PRis as determined by cell-free 
FRET based assay are given in Table 3.4 along with their simulated binding scores for 
comparison. The Ki for pepstatin A by this analysis method was 420 nM (literature value 
500 nM)?8 All of the C60 containing samples showed better inhibition than the non-C60 
control by ~ 1000 fold. The C6o control, Fmoc-Phe( 4-NH2)-0H, had in inhibition constant 
of> 1 0 J.lM, in essence, no inhibition in comparison with any of the fullerene amino acids, 
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which all exhibited at least nM inhibition. Inhibition constants of> 10 f..!.M are outside the 
determinable range by this analysis method. From this we can conclude that it is the 
presence of C6o that is responsible for the observed inhibition. Both of the Fmoc 
protected amino acids (Fmoc-Baa, 36 nM, and 2.6, 110 nM) showed improved inhibition 
over their free amine counterparts (Baa, 119 nM, and 2.14, 120 nM) supporting our 
hypothesis that the Fmoc protecting group forms favorable interactions with the 
hydrophobic binding pocket. In fact, any protecting group on the amino moiety improved 
the observed inhibition in comparison to the free amine, as evidenced by the Boc-Baa 
derivative, Ki 80 nM. However, compound 2.6, Fmoc-Phe(4-aza-C60)-0H, was about 
three times less potent than the analogous Fmoc-Baa despite the fact that their 
deprotected analogs showed nearly equivalent inhibition. 
Table 3.4. Inhibition constants of C6o amino acid PRis and controls. 
Inhibition Experimental binding Simulated binding 
Compound 
constant, Ki energy energy 
(nM) (kJmol"1) (kJmol"1) 
Fmoc-Phe-OH > 10000 -24.9 
pepstatin A 420 -36.3 
Boc-Baa 80. -40.5 
Fmoc-Baa3 36 -42.8 -46.69 
Baa3 119 -39.7 -38.83 
2.6 110 -39.7 -49.47 
2.143 120 -39.8 -41.75 
a Indicates collaborators results shown for comparison to other fullerene inhibitors. 
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The inhibition constant of the C6o peptides and controls as determined by FRET 
based assay are given in Table 3.5 in addition to the simulated binding energies for 
comparison. The most notable observation from the peptide experiments was that the 
predictive modeling program highly overvalued the inhibition of all of the peptide 
inhibitors while the more simple amino acid PRis were well estimated. A possible source 
of the discrepancy is that the peptide inhibitors are much more flexible and, particularly 
in the case of the Lys residues, have many possible conformations of the R sidechains. In 
addition to the flexibility, the peptide inhibitors are much larger and possibly not well 
represented by the haloperidol crystal structure used in the MD simulations. In this 
regard, a crystal structure of HIV -1 PR with a peptide inhibitor, such as pepstatin A, may 
provide a more accurate starting point for the MD simulations of the larger peptide 
inhibitors. 
Table 3.5. Inhibition constants of C6o peptides and control. 
Compound 
pepstatin A 
2.6 
3.18 
3.2 
3.3 
SA-Lys3-0H (3.4t 
Fmoc-Phe-Pro-Hyp-Lys (3.5) 
Inhibition 
constant, Ki 
(nM) 
420 
110 
85 
120t 
76 
6310 
> 10000 
Experimental binding 
energy 
(kJmor1) 
-36.3 
-39.7 
-40.3 
-39.4 
-40.6 
-29.7 
-23.8 
Simulated 
binding energy 
(kJmor1) 
-49.47 
-58.32 
-50.38 
-50.30 
a Indicates collaborators results shown for comparison to other fullerene inhibitors. 
t Indicates result from single data set. 
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In our investigation into the inhibition of HIV -1 PR with fullerene peptides we 
wanted to determine if just the presence of a hydrophobic moiety on a peptide sequence 
would have an effect on the observed inhibition of PR. In this regard, there was no 
suitable molecule that can mimic the hydrophobicity, size, and shape of C60. Stearic acid 
(SA) has been shown to be membranotropic in much the same way as C60/ 9 and for that 
reason, it was chosen as a hydrophobic control. The SA-Lys3 control (3.4) showed 
inhibition of approximately 6.3 f...LM, better than other controls but still well below the 
potency of the C6o peptides. The inhibition constant of another non-C60 control peptide, 
Fmoc-Phe(4-NH2)-Pro-Hyp-Lys (3.5), was determined to be >10 f...LM, demonstrating 
again that the observed inhibition of the reaction velocity was due to C60 and not a result 
of the dipeptide recognition element, Phe-Pro. 
All of the peptide inhibitors showed improved inhibition over their C6o amino acid 
base; however, none were as effective as our most potent inhibitor, Fmoc-Baa (Ki 36 
nM). The most active of the peptide inhibitors was compound 3.3 with two 
hydroxyproline residues, Ki 76; compound 3.3 was much more active than compound 
3.2, Ki 120, with only one hydroxyproline residue. It is unknown if the observed increase 
in binding affinity is due to better placement of the second hydroxyl moiety in regards to 
the aspartyl residues or if it is due to the increase in H-bonding opportunities; however 
the ~~G is worth approximately that of a H-bond. Regardless, the Phe-Hyp dipeptide 
sequence does seem to be recognized by HIV-1 PR as we hypothesized. Compound 3.1, 
the poly-Lys peptide, also showed improved inhibition over the C6o amino acid base. 
However, without a crystal structure of compound 3.1 in the binding pocket it is 
impossible to determine if the positively charged Lys residues are forming a salt bridge or 
if the improved affinity is due to H-bonding. Calculation of the MG between 3.1 and 2.6 
reveals that a salt bridge, worth about 12-17 kJ.mol"1, is probably not the cause of the 
increase, which was approximately- 0.6 kJ.mol"1• 
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In comparison to currently marketed protease inhibitors, none of ours have yet 
achieved sub-nM levels of inhibition and therefore are not yet viable drug candidates. 
However, our results with both the amino acids and the peptides are encouraging 
indicators that the achieved inhibition may be tuned with minor alterations to both the 
peptide and amino acid structure. It should also be noted that almost all of our fullerene 
inhibitors show higher levels of inhibition in comparison with the most potent previously 
reported fullerene derivative (1 03 nM). 
Given that all of the peptide sequences improved the inhibition of the base 
fullerene amino acid, it is reasonable to assume that they will do the same for our other 
C6o amino acids. Since our most potent inhibitor was Fmoc-Baa, in future studies it 
should be used as the C6o amino acid base despite the length of time required to make it. 
In addition to the change in the amino acid base, in future studies the length of the 
peptides should be increased by one Lys residue or more. Initially, when designing the 
peptides we used Lipinsky's rule of five for drug compounds as a guideline. All of our 
designed peptide inhibitors violated these rules at least partially and therefore a minimum 
sequence length was used for them all. However, HIV-1 PR recognizes peptides of at 
least five residues most efficiently.15 We know that cationic fullerene peptide sequences 
cross a cellular membrane easily,30 therefore we surmise that we would not sacrifice 
membrane permeability by increasing the number of Lys residues on the tail and could 
potentially improve the molecular recognition with HIV -1 PR with the addition. Future 
work should maintain the Hyp2 dipeptide subunit but should also include two or more 
Lys residue on the C-terminal end. This structural modification should improve 
solubility, make the peptide more recognizable by PR, and improve the affinity through 
H-bonding. 
The unattainable goal thus far in the field of HIV -1 PR inhibition is an inhibitor 
that binds equally well to the mutated strains of PR as to the native form. Given that point 
mutations usually occur within the hydrophobic binding pocket, and those mutations are 
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still hydrophobic residues, it is reasonable to infer that the non-specific hydrophobic 
interaction of C6o with the binding pocket of mutated strains will still be strong. Other 
questions about the specific interactions of C6o with HIV -1 PR could be determined by a 
crystal structure of one of the C6o inhibitors, such as Fmoc-Baa, in the binding pocket. 
Conclusion 
We have reported the synthesis of three, novel fullerene peptide sequences and 
investigated their inhibition ofHIV-1 PR. We have determined that C60 amino acids are a 
good base structure in the design of protease inhibitors and that their inhibition can be 
improved upon by the addition of designer peptide sequences. We found that the most 
potent of the C6o based inhibitors was Fmoc-Baa (Ki 36 nM) due to the electrostatic 
interactions of both the Fmoc protecting group and C6o· Of the peptide inhibitors, the 
Hyp-Hyp-Lys (Ki 75.1) sequence showed the highest level of inhibition and improved the 
inhibition of its C6o amino acid base, 2.6, (Ki 1 08). Based on these findings, we can 
reason that HIV-1 PR may be able to recognize the Phe-Hyp dipeptide sequence; 
however, it is not known if that recognition would result in specificity to HIV-1 PRover 
cellular proteases. Given the improvement in the observed protease inhibition achieved 
by the addition of the peptide tail to compound 2.6, it is reasonable to assume that the 
inhibition of Fmoc-Baa may also be improved by such an addition. While our C6o peptide 
inhibitors are not yet viable drug candidates, the results of these experiments are 
prom1smg. 
Experimental 
The FRET peptide substrate (sequence not given), HIV-1 PR, and assay buffer A 
(Tris, Glycerol, KCl, DTT, and EDTA with 500mM KCl, pH 4.7) were provided in the 
ProAssay™ HIV- Protease kit from ProteinOne. The peptide sequence of the FRET 
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peptide substrate is derived from the native p17/p24 cleavage site on Prgag (native 
substrate) for HIV-1 protease. Protected amino acids were purchased from Chem-Impex 
International, Inc., unless otherwise specified, and used without further purification. All 
inhibitor peptide sequences were purchased from BioSynthesis, Inc. in the crude form on 
Wang resin. Solvents were purchased from Sigma Aldrich and used without further 
purification. All other chemicals and reagents were purchased from Sigma-Aldrich. High 
performance liquid chromatography (HPLC) was performed on a Varian ProS tar 
instrument using a Varian Dynamax Cts column (250 x 21.6 mm) for purification when 
necessary. Mass spectrometry measurements were performed on a Bruker Auto Flex 
11/ToF/ToF and a Bruker Electrospray Ionization/1-1ToF. a.-Cyano-4-hydroxycinnamic 
acid were used as the matrix to characterize all peptides by MALDIITOF (positive 
mode). UV -vis spectra were recorded on a Varian Cary 5000 spectrometer. Fluorescence 
data was recorded on a BioTek Synergy 4 fluorescence platereader. 
General fullerene peptide synthesis. All peptides were purchased on the resin 
with orthogonal protection for Fmoc SPPS on the side chains and N-terminus. The 
fullerene amino acid, or a control amino acid, was coupled to the peptide sequence 
through published literature methods in a 3:1 amino acid to peptide ratio.31 The reaction 
mixture was shielded from light throughout the synthesis and purification. Peptides were 
cleaved from the resin using 20% TF A with 2.5% TIPS in DCM and precipitated with 
cold diethylether then washed with ether (3 x 50 mL). The crude peptide was dissolved in 
an appropriate solvent or buffer and mixed with a small amount of Cts coated silica gel 
and immediately filtered to remove the salts for analysis then lyophilized and stored 
under vacuum in the dark. When necessary the peptide was purified by HPLC (Cts prep 
scale, 95:5 to 5:95 0.1% formic acid and isopropanol, 65 min). The major impurity 
present is C60 by ESI MS. 
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Fmoc-Phe(4-aza-C6o)-LysJ-OH (3.1). The crude peptide, Fmoc-Lys(Boc)-
[Lys(Boc)]z-Wang resin (215.5 mg, 0.2 mmol/gresin), was added to a 10 mL SPPS 
synthesis vessel. DMF was used to swell the resin for 1 h then filtered. The Fmoc 
protecting group on the terminal Lys residue was removed with 25% piperidine in DMF 
(2 x 10 mL) afterwhich the resin was rinsed with DMF (3 x 10 mL). Compound 2.5a 
(150 mg, 0.132 mmol), HOBt (17.81 mg, 0.132 mmol), PyBop (68.64 mg, 0.132 mmol), 
and diisopropylethylamine (DIEA, 68.9 J.!L, 0.396 mmol) were dissolved in DMF:CH2Ch 
(1 :2, 8 mL) and sonicated for two minutes then added to the resin. The synthesis vessel 
was always kept in the dark and was mixed for 24 h. The excess reagents were filtered 
away and the resin was washed with CH2Ch (3 x 10 mL), and DMF (3 x 10 mL) then the 
resin was shrunk with MeOH (3 x 10 mL). The peptide was cleaved from the resin with 
20:2.5:77.5 TFA:TIPS:CHzCh and precipitated and washed with the addition of cold 
EtzO (3 x 50 mL). ESI/ToF shows the major impurity is C6o· To remove C60 the peptide is 
dissolved in DMSO and filtered through a Cts silica plug. The product was lyophilized to 
dryness. Yield: 33 mg, 50%. ESI/Tof(M+1) requires mlz 1505., found mlz 1505.45. 
Fmoc-Phe(4-aza-C60)-Pro-Hyp-Lys (3.2). The crude peptide, Fmoc-Pro-
Hyp(tBu)-Lys(Boc)-Wang resin (102.63, 0.217 mmol/gresin, 0.022 mmol), was added to a 
10 mL SPPS synthesis vessel. DMF was used to swell the resin for 1 h then filtered. The 
Fmoc protecting group on the terminal Lys residue was removed with 25% piperidine in 
DMF (2 x 10 mL) afterwhich the resin was rinsed with DMF (3 x 10 mL). Compound 
2.5a (75 mg, 0.067 mmol), HOBt (9.04 mg, 0.067 mmol), PyBop (34.83 mg, 0.067 
mmol), and diisopropylethylamine (DIEA, 35 J.!L, 0.201mmol) were dissolved in 
DMF:CH2Ch (1 :2, 8 mL) and sonicated for two minutes then added to the resin. The 
synthesis vessel was always kept in the dark and was mixed for 24 h. The excess reagents 
were filtered away and the resin was washed with CH2Ch (3 x 10 mL), and DMF (3 x 10 
mL) then the resin was shrunk with MeOH (3 x 10 mL). The peptide was cleaved from 
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the resin with 20:2.5:77.5 TFA:TIPS:CH2Ch and precipitated and washed with the 
addition of cold EtzO (3 x 50 mL). The peptide was pure as cleaved off the resin by 
ESI!ToF with a minor C6o impurity. The product was dissolved in MeCN:H20 (1:1, 1.0 
mL) and lyophilized to dryness. Yield: 53 mg, 80%. ESI/Tof (M+ 1) requires m/z 
1459.41, found mlz 1459.34. 
Fmoc-Phe(4-aza-C6o)-Hyp-Hyp-Lys (3.3). Prepared in a similar manner to 
compound 3.2 using the crude peptide, Fmoc-Hyp(tBu)-Hyp(tBu)-Lys(Boc)-Wang resin 
(1 00.40 mg, 0.22 mmol/gresin, 0.022 mmol), compound 2.5a (75 mg, 0.067 mmol), HOBt 
(9.04 mg, 0.067 mmol), PyBop (34.83 mg, 0.067 mmol), and diisopropylethylamine 
(DIEA, 35 J.!L, 0.201mmol). Yield: 27.6 mg, 85%. ESI!Tof (M+1) requires mlz 1475.9, 
found mlz 1476.23. 
Stearic Acid-Lys3 (3.4). Prepared in a similar manner to compound 3.1 using the 
crude peptide, Fmoc-Lys(Boc)-[Lys(Boc)]z-Wang resin (74.88 mg, 0.266 mmol/gresin, 
0.02 mmol), stearic acid (17 mg, 0.06 mmol), HOBt (8.07 mg, 0.06 mmol), PyBop (31.1 0 
mg, 0.06 mmol), and diisopropylethylamine (DIEA, 31.2 J..tL, 0.179 mmol). Yield: 12.05 
mg, 90%. ESI/Tof (M+ 1) requires mlz 669.56, found mlz 669.54. 
Fmoc-Phe(4-NHz)-Pro-Hyp-Lys (3.5). Prepared in a similar manner to 
compound 3.2 using the crude peptide, Fmoc-Pro-Hyp(tBu)-Lys(Boc)-Wang resin (71.6 
mg, 0.22 mmol/gresin), Fmoc-Phe(4-NHz)-OH (20.0 mg, 0.047 mmol), HOBt (6.3 mg, 
0.047 mmol), PyBop (24.3 mg, 0.047 mmol), and diisopropylethylamine (DIEA, 24.4 
J.!L, 0.140 mmol) Yield: 11 mg, 90%. ESI/Tof (M+1) requires mlz 767.91, found mlz 
767.34. 
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Determination of substrate Km. The Km of a substrate is determined by 
evaluating the initial velocity of substrate hydrolysis at various substrate concentrations 
in the absence of an inhibitor. The concentrations of substrate assayed by this method 
were from 16.5 - 0.2 !J.M. Substrate hydrolysis was followed as an increase in 
fluorescence (excitation/emission 490/530 nm). Data was collected at 25 oc for one hour, 
or as long as the data remained linear, at one minute increments. The total reaction 
volume was 25 !J.L. The kinetic parameters Km and V max were determined by fitting the 
reaction progress curve to the M-M equation. Figure 3.10 shows the Michaelis-Menten 
plot of our enzyme kinetic data with HIV -1 PR ( red curve). All data presented was the 
average of at least duplicate measurements. The Km of our substrate was determined to be 
0.6 !J.M. All future kinetic inhibition assays were performed at a substrate concentration 
of -1 !J.M. We confirmed that our enzyme was following Michaelis-Menten kinetics by 
fitting the data to the equation for a standard rectangular hyperbola (Figure 3.14, green 
curve). 
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Figure 3.14. The red curve is the plot of M-M type kinetics observed during the 
hydrolysis of the FRET substrate by HIV -1 PR where V max = 1.459 and Km = 0.58 !J.M. 
The green curve represents the same data fit to the equation of a standard hyperbola. 
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Determination of total active site concentration [Et]. The total active site 
concentration values were determined by a cell-free FRET based assay. Typically, 1 pmol 
(12 !-LL, 0.09 !-LM) of HIV -1 PR was added to 13 I-LL of dilution buffer A containing the 
substrate at a concentration near its Km ( 1 !-LM) and various concentrations of a tight 
binding inhibitor dissolved in DMSO (final concentrations from 100 1-1M to 0.01 nM). 
The final concentrations of DMSO were kept below 2.5% (v/v). Substrate hydrolysis was 
followed as an increase in fluorescence (excitation/emission 490/530 nm). Data was 
collected at 25 oc for one hour, or as long as the data remained linear, at one minute 
increments. The total reaction volume was 25 1-1L. All data presented is the average of at 
least duplicate measurements. The solubility of the tight binding inhibitor was sufficient 
for all the concentrations used. The DMSO/water mixture was used in a 1:9 ratio and no 
precipitation was observed. Linear regression was performed on a plot of fractional 
velocity (v/v0 ) versus inhibitor concentration to determine the total active site 
concentration (Figure 3.15). When the fractional velocity plateaus near zero, the enzyme 
is said to be completely, or nearly completely, inhibited and the rate of the reaction is 
determined simply by dissociation of the enzyme-inhibitor complex. The concentration of 
a tight binding inhibitor is said to be equal to the total active cite concentration, [Et], at 
the x-intercept of the linear portion of the data, before the fractional velocity plateaus. 
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Figure 3.15. Above is the plot of fractional velocity (v/v0 ) versus inhibitor concentration 
used to determine the total active site concentration of the enzyme, [Et] = 37.5 nM. 
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Inhibition assay. The Ki values were determined by a cell-free FRET based assay 
using the FRET peptide substrate. Typically, 1 pmol (12 JlL, 0.09 JlM) ofHIV-1 PR was 
added to 13 JlL of dilution buffer A containing the substrate at a concentration near its Km 
(1 JlM) and various concentrations of the inhibitor dissolved in DMSO (final 
concentrations from 100 JlM to 0.01 nM). The final concentrations ofDMSO were kept 
below 2.5% (v/v). Substrate hydrolysis was followed as an increase in fluorescence 
(excitation/emission 490/530 nm). Data was collected at 25 °C for one hour, or as long as 
the data remained linear, at one minute increments. The total reaction volume was 25 JlL. 
The solubility of the compounds was sufficient for all the concentrations used. The 
DMSO/water mixture was used in a 1 :9 ratio and no precipitation was observed. 
Inhibition data was analyzed using the equation for competitive inhibition according to 
Williams and Morrison.32 The data was fit using non-linear regression with the Graphpad 
Prism software. 33 
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Chapter4 
Synthesis of Highly Functionalized Graphene 
Introduction 
Recent years have brought about a renewed interest in graphite or specifically individual 
or few-layer (n < 5) sheets of graphite called graphene. The unique physical and electronic 
properties of graphene make it attractive as a substitute for other more costly carbon 
nanostructures. 1 Due to its similarities and differences with other carbon nanostructures, 
graphene (2 dimensional, 2D) is no longer the underappreciated parent of fullerenes (OD) and 
carbon nanotubes (lD) (Figure 4.1). The ability to individualize sheets of graphene has brought 
the material to the forefront of carbon research. 2 And while graphene does provide similar scale, 
properties, and reaction pathways as fullerenes and CNTs, it does so at a fraction of the cost. 
Regardless of the novel electronic properties of graphene, it also presents an inexpensive, large 
surface area scaffold for the covalent attachment of organic molecules. Covalent funtionalization 
provides a robust material for use as a scaffold and as a means of incorporating additional 
functionality. Incorporation of functionalized graphene sheets into composite materials may 
enhance mechanical and electronic properties. 
The majority of reports of covalently functionalized graphene use graphene oxide (GO) 
as the starting material.3 While the structure of GO has been shown to include regions of 
unoxidized benzene rings, the presence of islands of epoxides and hydroxyl groups on the basal 
plane and carboxylic acids around the perimeter of the sheet make GO extremely hydrophilic. In 
addition, graphene oxide contains a large percentage of water requiring more than four weeks to 
dry post synthesis.4 While the GO route does result in highly functionalized graphene sheets, the 
drawbacks are that reactions using GO as the starting material are limited to aqueous or polar 
conditions and more important a second reduction step is necessary to remove the excess oxides 
still present. 3 A simpler route to widespread functionalization is therefore desirable. In this 
regard, we report a new, high yield method of covalently functionalizing graphene sheets. 
I 
/ 
Figure 4.1. Three of the carbon allotropes are presented above. 1 
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It has been shown that both CNTs and fullerenes are easily functionalized by nitrene 
addition, generated in-situ by thermal decomposition of azido starting materials.5 The result is 
high density functionalization of the nanostructure surface through a [2+ 1] cycloaddition to the 
C-C double bonds forming an aziridino-ring linkage, however, this methodology has only been 
applied to curved or strained (i.e. reactive) carbon nanostructures. The alkyl and aryl azido 
starting materials are easily synthesized on the gram scale and azides offer a wide range of 
functional group tolerance. 6 For our purposes, the azido moiety resides on the R side chain of the 
amino acid phenylalanine (Phe) allowing incorporation of two new chemical handles on the 
graphene scaffold for subsequent reaction. In this regard, the graphene sheet could be used as a 
solid support for solid phase peptide synthesis (SPPS) of a sequence on the graphene surface. 
The addition of sequences of amino acids to the graphene surface should impart water solubility 
and some level of biocompatibility. 
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Results and Discussion 
The high yield functionalization of graphitic materials through nitrene addition has been 
investigated. The nitrene was generated by the thermal decomposition of azido starting materials, 
in this case, a Boc protected amino acid, phenylalanine. The synthetic graphite was exfoliated 
into a-dichlorobenzene (ODCB) through sonication prior to the nitrene addition. 
Microcrystalline graphite was exfoliated in ODCB to make a clear gray solution of 
graphene sheets without the use of harsh oxidizing conditions. 7 Previous reports using this 
exfoliation method use high-shear mixing, or homogenization, to further exfoliate the sample 
before centrifugation. For our future purposes of using the graphene sheet as a support for SPPS, 
the large lateral dimensions of the starting material were desirable, and therefore, the 
homogenization step was eliminated. It is worth noting that this reaction was not reproducible 
using thermally expanded graphite intercalation compounds (GIC)8 as the starting material. 
Given that GICs use a variety of reactive molecules to intercalate between graphene layers,4 side 
reactions with reactants are inevitable, thus limiting their use as graphitic starting materials as 
well. 
(2.4) 
exfoliated 
~G 
ll , ODCB. 
4d 
R 
A 
N 
N 
' R 
N-R 
Boc-Phe(4-N-J.IG)-OH (4.1) 
Scheme 4.1. Reaction scheme showing the nitrene addition to exfoliated uG. 
In a typical reaction the exfoliated J.!G solution was stirred with Boc-Phe( 4-N3)-0H (2.4) 
at refluxing temperatures, ~ 180 °C, for four days. The reaction was filtered over a 0.2 Jlm PTFE 
filter paper, and washed to remove any umeacted Phe(4-N3)-0H (Scheme 4.1). The product 4.1 
93 
was found to make an amber colored solution in DMSO, averaging 0.06 mg.mL-1 after 10 min. of 
probe sonication and centrifugation (3400 RPMs for 15 min). The product also proved sparingly 
soluble in other organic solvents such as DMF, toluene, and chloroform in comparison to the J.lG 
starting material. To confirm the chemical modification FTIR spectroscopy, Raman 
spectroscopy, and XPS were utilized. 
The elemental composition of the product 4.1 was determined by XPS, confirming the 
presence of the phenylalanine (Figure 4.2). The oxygen (16.1%) and nitrogen (13.5%) content 
are consistent with the presence of the phenylalanine substituent (Figure 4.3). The XPS data of 
4.1 indicates 13:1 carbon to phenylalanine ratio. However, we expected to see approximately a 
2:1 oxygen:nitrogen composition instead we observed a 1.2:1 oxygen to nitrogen ratio. We 
suspected that the discrepancy was due to the loss of the Boc protecting group, which can occur 
at 180 °C;9 however, the Fourier transform infrared (FTIR) spectra of 4.1 (Figure 4.4) showed 
the characteristic absorption of a secondary carbamate carbonyl stretch at 1655 cm-1, indicating 
there was only partial loss of the Boc protecting group if any. In addition, the spectrum shows 
absorption in the carboxylic acid (~3200 cm-1 stretch and 1438 cm-1 bend) and the amide C-N 
regions (1319 cm-1) relative to the J.lG starting material. Also present in the spectrum are the NH 
stretch (3426 cm-1) of the Boc amino protecting group and the prominent C-N amine stretch at 
1022 cm-1 ofthe aziridino linkage. 
High resolution transmission electron microscopy (TEM) of 4.1 show multi- or few-layer 
graphene sheets (n < 5) layered over each other, with an average length of 300 - 500 nm and with 
varying widths. The formation of multi- or few- layer sheets is further supported by selected area 
electron diffraction (SAED, Figure 4.5 inset) and fast Fourier transform (FFT, Figure 4.5) in 
selected areas. SAED during TEM analysis showed that of a hexagonal close packing (AB) 
crystallite with six point hexagonal symmetry (Figure 4.5). No ring-like diffraction patterns are 
observable as would be the case for graphite with random stacking or amorphous carbon; 
however, additional spots with hexagonal symmetry but misaligned with respect to each other 
indicated multi-layers. 
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Figure 4.2. Presented above is the XPS survey scan of 4.1 showing the presence of C, 0 , N, and 
F (attributed to fluro-grease). 
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Figure 4.3. The high-resolution XPS Cls, Nls and Ols spectra of 4.1 (y-axis counts/second). 
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Figure 4.4. Thin film IR spectra of compound 4.1 taken on a KBr salt plate. 
Figure 4.5. TEM micrographs of 4.1 showing (a) 50000x and (b) 80000x stacked, few- or multi-
layer sheets of 4.1; (c) SAED confirming few- or multi- layer graphene sheets; (d) selected area 
from (b) with FFT inset. 
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The atomic force microscopy (AFM) of 4.1 confirmed the presence of graphene sheets 
with a wide variety of lateral dimensions from 150 nm to > 5 J.lm. The thickness of the observed 
sheets ranged from 0.5 nm to -2.5 nm (Figure 4.6). The theoretical height of our Phe functional 
group is -0.75 nm (not including the aziridino ring linkage), correlating to the addition of 1.5 nm 
to the thickness of the graphene sheet if functionalization occurs on both sides. Several groups 
have reported a .height of -1 nm for GO sheets with some variability. 10 Our analysis of 4.1 shows 
a variety of sheet thicknesses; however, we surmise that the thinnest sheets, 0.5 nm, are only 
edge functionalized while the thickest at 2.5 nm are basal plane functionalized on both sides. 
Based on both the TEM and AFM characterization, we conclude that few-layer (n < 5) graphene 
sheets are produced by this reaction method. 
nm 
0~------------------------------------~ 
Lrl 
2 . 5 5. 0 
!Jm 
7.5 10.0 
Figure 4.6. The AFM image and associated height profile of Phe-N-J..!G (4.1), spin coated on a 
cleaved mica substrate from CHCh are shown above. 
Scanning TEM (STEM) images of 4.1 (Figure 4.7) deposited from DMSO on a lacey 
carbon grid show few-layer sheets, the majority of which had lengths of over 1 J.lm and widths of 
about 500 nm. However, some sheets were as small as 150 x 300 nm, in agreement with TEM 
and AFM measurements. EDX analysis of the dark spots showed the presence of oxygen in the 
spots but not nitrogen, therefore, we were unable to definitively confirm that the spots are 
phenylalaine substituents. 
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Figure 4.7. Bright Field-STEM images of 4.1 deposited from DMSO showing (a) few layer 
graphene sheets of width measuring 150, 200, and 275 nm; (b) several large groups of >1 J..Lm 
single and few layer sheets along with smaller aggregates of flakes; (c) 375 nm x 1.2 J..Lm sheet 
on top of 1.3 x 0.5 J..Lm sheet; (d) sheet with dark spots covering the basal plane. 
The extent of functionalization was obtained from thermogravimetric analysis (TGA) 
over the temperature range of 130 - 850 oc in agreement with the decomposition of 
phenylalanine (Figure 4.8). Assuming no mass loss due to J..LG and taking into account the 
carbonaceous material remaining from phenylalanine, the final product 4.1 was determined to be 
69o/o phenylalanine (wt.%). This corresponds to one Boc-Phe-N substituent per 10 J..LG carbons 
(XPS data shows 13:1 C:Phe-N). It should be noted, however, that each Phe substituent is 
bonded to two carbon atoms (Scheme 4.1 ). It has been shown previously that graphene is 
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preferentially functionalized along it edges. 11 However, by our synthesis method, even with the 
smallest sheets of 4.1 ( 150 x 300 nm by STEM), if the functionalization is limited to the edges, 
only 2-3% by mass of the sample is attributable to Phe-N. Assuming the entire mass loss by 
TGA is due to covalently bonded Phe, to achieve 69% by mass functionalization of 4.1, the 
nitrene addition could not occur solely at the edges of the sheets. STEM images (Figure 4.7) 
show dark spots along the basal plane of the sheets but EDX analysis of the spots could not 
definitively confirm that they are Phe. We conclude, therefore, that by our route, 
functionalization is not limited to the edges and the resulting structure is analogous to that of 
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Figure 4.8. The TGA of 4.1 showing 69% normalized mass loss corresponding to a 10: 1 C to 
Boc-Phe-N ratio. Note: 27% of Boc-Phe(N3)-0H (SM), remains after heating to 850 oc under Ar 
with a one hour hold time. 
Raman spectroscopy (514 nm excitation) of 4.1 showed a D:G ratio of 0.78 in 
comparison to that of exfoliated f.lG at 0.66 (Figure 4.9a and b). While there is not a significant 
change, this could be due to the distribution of functional groups on the surface and/or an effect 
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of the size of the sheets. 12 The most noticeable feature in the spectrum of 4.1 is the loss of the 2D 
peak (ca. 2700 cm-1) . Most previous reports of functionalized graphene omit mention of this 
peak. 11 ' 13 The only material reported to show a similar loss of the 2D peak is graphene oxide 
(GO), 14 in which the graphitic structure is almost completely oxidized. Based on the similar 
spectra of 4.1 to GO (Figure 4.9b and c), the absence of the 2D peak indicates the lack of sp2 
carbons present and, therefore, the high degree of functionalization. Thermolysis of 4.1 at 600 oc 
for 12 hrs produced a black powder with a D:G ratio of 0.67 and a partially restored 2D peak 
(Figure 4.9 d) similar to that of the exfoliated f.lG sample. It should be noted that the bulk f.lG 
material prior to exfoliation had a D:G ratio of 0.25 indicating possible modification to the 
electronic framework simply through sonication in ODCB. 15 
(c .__) _...J.--____ _ 
100 600 1100 1600 2100 2600 
Raman shift {cm-1) 
Figure 4.9. The Raman spectra of (a) exfoliated f.lG, D:G 0.66; (b) 1, D:G 0.78; (c) graphene 
oxide, D:G 0.77 (d) annealed 1, D:G 0.67 are presented above. 
As mentioned previously the XPS spectra of 4.1 did not show the expected 2:1 oxygen to 
nitrogen ratio that we expected. Given that the Boc protecting group has been shown to be labile 
at temperatures near the reaction temperature, 180 °C, the concern was that the observed high 
yield functionalization may be due to polymerization of phenylalanine on the surface of the 
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graphene. To determine if polymerization of Phe was occurring, we repeated the reaction with a 
methyl ester of Boc-4-azido-Phe ( 4.2). Protection at both carboxy and amino terminus should 
eliminate the possibility of peptide formation. When the graphene functionalization was repeated 
with 4.2, it was performed at a slightly lower temperature to prevent the loss of the Boc group. 
The product ( 4.3) was worked up as previously stated. The high resolution XPS spectra of 4.3 
showed 13.21 o/o N and 20.58o/o 0, much closer to the 2:1 ratio we expected, but probably still 
with some loss of the Boc group (Figure 4.1 0). The nitrogen content as determined by XPS was 
used to calculate the carbon to Phe-N ratio and confirm the results we obtained by TGA. The 
carbon to Phe-N ratio of 4.1 and 4.3 were calculated to be 13: 1 and 12: 1 respectively from XPS 
data. Given that the degree of functionalization for both samples was similar, even with 4.3 
protected at both ends, we felt comfortable with our determination that high yield 
functionalization of the graphene surface was occurring. 
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Figure 4.10. The high-resolution XPS spectra of 4.3, Cls, Nls and Ols spectra (y-axis arb units) 
showing the presence of C (66.20%), 0 (20.58%) and N (13.21 o/o). The data corresponds to 12:1 
carbon to phenylalanine ratio for the product 4.3. 
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Conclusions 
In conclusion, we have reported a high yield method of covalently functionalizing 
exfoliated graphene by nitrene addition in ODCB. The addition results in few-layer, DMSO 
soluble graphene sheets. Given the extensive range of organic azides accessible by a simple 
diazo-transfer reaction, 6 this method offers a route to a wide variety of functional addends. The 
advantages of our method are as follows: 1) no final reduction step is requi~ed, 2) a wide variety 
of functional addends are accessible, 3) reactions are not limited to aqueous/polar conditions, and 
4) highly functionalized, few-layer graphene sheets are produced. The control over the extent of 
functionalization is currently under investigation, as well as the feasibility of 4.1 as a solid phase 
support for peptide synthesis on the surface of a graphene scaffold. 
Experimental 
ODCB was purchased from Fisher Scientific and used as received. Microcrystalline 
synthetic graphite (<20 J.tm) and Boc-Phe(4-NH2)-0H and all other reagents were purchased 
from Sigma-Aldrich and used as received. Sonication was performed with an ultrasonic 
processor (Cole-Parmer) with probe attachment at 30% amplitude. Centrifugation was at 3300 
rpm for 15 min. (Sorvall ST 16, RCF33oo = 2045) unless otherwise specified. All reactions are 
performed under an inert atmosphere. 
All XPS data was acquired on a Physical Electronics, Inc. Phi Quantera instrument with 
monochromated Al-Ka. TEM images were collected with a Jeol JEM-2100F advanced field 
emission electron microscope with an accelerating voltage of 120- 200 kV. AFM measurements 
were obtained using a Digital Instruments NanoScope lila scanning probe microscope in tapping 
mode. AFM samples were spin coated from CHCh onto cleaved mica substrates. STEM 
micrographs were collected with a Hitachi S5500 scanning transmission electron microscope. 
ODCB suspensions. Synthetic microcrystalline graphite (50 mg) was added to 20 mL 
ODCB. The mixture was probe sonicated for one hour. The slurry was then centrifuged for 30 
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minutes at 4400 rpm. High shear mixing of the ODCB/J.!G suspension was not performed in an 
effort to maintain the large lateral dimensions of the J.!G starting material. Therefore, our 
dispersions may not be exfoliated to the same degree as previous examples using this method. 7 
The supernatant of the J.!G solution was used in the nitrene reaction. Resuspension and filtration 
of the JlG pellet yielded 41 mg of recovered J.!G. 
Boc-Phe(4-N-J..1.G)-OH (4.1). Boc-Phe(4-N3)-0H (150 mg in ODCB, 2 - 3 mL) was 
added to the exfoliated JlG solution (-5 mL) in a 50 mL 3-neck flask fitted with a condenser, a 
thermometer, a stopper and a stir bar. The reaction was diluted to 25 mL with ODCB and the 
temperature was maintained at 165 °C for 4 days under Ar after which the brown suspension was 
filtered over a 0.2 urn PTFE filter paper. The filter cake was washed copiously with MeOH, 
CHCh, and DMF to remove any unreacted Boc-Phe(N3)-0Me. The fine brown powder was dried 
in an oven overnight at 125 °C. Final yield: 110 mg. 
Boc-Phe(4-NJ)-0Me (4.2). In a 250 mL Shlenk flask, Boc-Phe(4-NJ)-OH (153.6 mg, 0.5 
mmol) was dissolved in MeOH (200 mL, seived) under an inert atmosphere. Two equivalents of 
chlorotrimethylsilane (TMS-Cl, 126.5 JlL, 1.0 mmol) were added to the stirring solution. After 
stirring at room temperature for 5 hours, the reaction mixture was dried on a rotary evaporator. 
The residue was dissolved in DCM and filtered to remove white precipitate. The filtrate was 
applied to an Si02 plug and eluted with ethyl acetate:hexanes (1: 1; Rr 0.85) followed by rotary 
evaporation. Yield= 43 mg, 0.14 mmol, 27%. 1H NMR (400 MHz, CDCh): 8 7.11 [2H, d, J(H-
H) = 8.35 Hz, CH], 6.96 [2H, d, J(H-H) = 8.47 Hz, CH], 4.98 [1H, d, J(H-H) = 7.76 Hz, NH], 
4.57 [1H, dd, J(H-H) = 5.91 Hz, J(H-H) = 14.07 Hz, CH], 3.71 (3H, s, CH3), 3.10 [1H, dd, J(H-
H) = 5.78 Hz, J(H-H) = 13.75 Hz, CH2], 3.01 [1H, dd, J(H-H) = 5.94 Hz, J(H-H) = 13.75 Hz, 
CH2], 1.42 (9H, s, tBu). IR (cm"1): VNJ 2115. 
103 
Boc-Phe(4-N-J.LG)-0Me (4.3). Boc-Phe(4-N3)-0Me (35 mg in ODCB, 2 - 3 mL) was 
added to the exfoliated f.lG solution (~5 mL) in a 50 mL 3-neck flask fitted with a condenser, a 
thermometer, a stopper and a stir bar. The reaction was diluted to 25 mL with ODCB and the 
temperature was maintained at 165 °C for 4 days under Ar after which the brown suspension was 
filtered over a 0.2 f.!m PTFE filter paper. The filter cake was washed copiously with MeOH, 
CHCh, and DMF to remove any unreacted Boc-Phe(N3)-0Me. The fine brown powder was dried 
in an oven overnight at 125 °C. Final yield: 14 mg. 
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Appendix A 
Collaborators Methods and Results 
Docking Simulations. The molecular docking simulation was performed using a 
the crystal structure of HIV-1 PR with the inhibitor haloperidol (PDB code:1AID). All 
waters of crystallization as determined by the crystal structure remained throughout the 
docking simulation but were freely rotatable and replaceable by ligand, i.e. inhibitor, 
docking. Two in silico docking algorithms FlexX and Glide Induced Fit Docking (IFD) 
were used for assessing the binding properties of each compound. A detailed description 
of the docking simulation is provided elsewhere. 1 
Inhibition Assay. The Ki values were determined by a spectrophotometric assay 
using the chromogenic peptide substrate LysAlaArgValNle*NphGluAlaNle-NH2 as 
described by Weber et al.2 Typically, 8-10 pmol ofHIV1-PR was added to 1 mL of0.1 M 
sodium acetate buffer (pH 4.7), 0.3 M NaCl, and 4 mM EDTA, containing the substrate 
at a concentration near the Km of the enzyme and various concentrations of the inhibitor 
dissolved in DMSO (from 0.1 mM to 0.01 nM). The final concentrations ofDMSO were 
kept below 2.5% (v/v). Substrate hydrolysis was followed as a decrease in absorbance at 
305 nm using a Cary 3 500 UV-vis spectrophotometer (Cambridge, UK). The HIV-1 PR 
remained stable over the whole reaction time. Inhibition data were analyzed using the 
equation for competitive inhibition according to Williams and Morrison.3 The solubility 
of the compounds was sufficient for all concentrations used in biological and solubility 
experiments. More specifically, in in vitro tests, the DMSO/water mixture has been used 
as a 1 :9 ratio, and no precipitation problems have been observed. 
The results of the MD simulations and inhibitory assay are given in Table A.1. 
xviii 
Table A.l. Collaborators results of C6o based HIV -1 PR inhibitors. 
Experimental Experimental Simulated 
binding affinity, binding energies, binding 
Structure energies, 
Glide/IFD 
(nM) (kJ/mol) (kJ/mol) 
~~ -39.75 -38.83 
RIS R 
*Cf ·c2 
-39.67 -38.28 
6600 4 -29.75 -36.65 
> 10000 4 > -28.72 -38.45 
-36.52 -39.04 
>10000 4 > -28.72 -33.93 
2 
3 
4 
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